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Abstract
Cancer patients often experience cachexia, a form of weight loss consisting mostly
of skeletal muscle wasting. Muscle wasting leads to physical disability, poor quality of
life, reduced tolerance to treatments and shorter survival. Although the causes of cancerrelated muscle atrophy have been studied for decades, the exact mechanisms through
which cancer and its treatments promote muscle wasting have yet to be defined.
The overall aim of this dissertation is to examine the mediators of muscle wasting
in cancer patients during their treatment and examine the modulatory role of exercise to
maintain muscle size and function. To address these aims, we studied two different
populations of cancer patients to examine the effects of tumor-related factors and
chemotherapy to cause muscle atrophy using an in vitro skeletal muscle system.
We examined whether tumor cells secrete factors to promote atrophy by evaluating
the effects of tumor-conditioned media (CM) from murine and human lung tumor cells
(hTCM) on cultured muscle myotubes. We hypothesized that conditioned media from
murine and human tumor cells would reduce myotube myosin content a marker for
atrophy, decrease mitochondrial content, and increase mitochondrial reactive oxygen
species production (ROS), all of which have been reported in model systems using murine
tumor cell CM.
Cancer patients frequently receive chemotherapy, some of which are known to be
myotoxic. Whether these drugs promote muscle wasting, however, is not clear. To address
this question, we assessed skeletal muscle structure and protein expression in 13 women
diagnosed with breast cancer, who were receiving adjuvant chemotherapy following
tumor resection, and 12 non-diseased controls. Furthermore, we evaluated the role of
individual chemotherapeutics (doxorubicin and paclitaxel) to cause atrophy,
mitochondrial loss and increased reactive oxygen species production in C2C12 cultured
muscle myotubes, as well as the modifying effects of a mitochondrial-targeted antioxidant.
Pre-clinical models show that exercise protects against the deleterious effects of
chemotherapy, although the mechanisms underlying these effects are not known. To
address this question, we utilized an in vitro model of exercise by treating C2C12
myotubes with doxorubicin (DOX; 0.2 μM for 3 days) with or without daily bouts of
electrical field stimulation (STIM).
Our results advance the field by showing that the treatments, and not tumorrelated factors, promote skeletal muscle atrophy. Moreover, exercise is effective at
countering the deleterious effects of chemotherapy and acts via mechanotransductive
signaling pathways.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW

A Review on Mediators of Cancer Related Skeletal Muscle Atrophy and the Role of
Electrical Stimulation as a Surrogate for Exercise

Blas Guigni and Michael Toth

Department of Molecular Physiology and Biophysics, Department of Medicine, Larner
College of Medicine, University of Vermont, Burlington, VT, 05405
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Introduction
Cancer-related muscle wasting is a multifactorial condition that negatively affects
patients’ prognosis and quality of life (84, 113, 164). Traditionally, cachexia has been
defined by a specified percentage of weight loss over time (i.e., 5% weight loss in the
preceding 6-12 months). However, the assessment of weight loss alone does not reflect
the complete scope of pathophysiologic changes or the clinical impact. The severity and
phenotypic presentation of cancer-related atrophy may vary, and often muscle wasting
may not be diagnosed (5, 42). Regardless, skeletal muscle loss is considered a meaningful
prognostic factor during cancer (7) and has been associated with higher incidence of
therapy toxicity, increased morbidity, and mortality (129, 156).
The pathogenesis and molecular mechanisms underlying cancer-related muscle
wasting have not been fully elucidated. Available evidence suggests an imbalance
between the rate of synthesis and protein degradation, although impaired defective
myogenesis may contribute as well. In addition, alterations in energy metabolism
involving mitochondrial dysfunction have been implicated in the wasting process (2, 41).
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Skeletal muscle structure and function
Skeletal muscle fibers (muscle cells) are composed of intracellular contractile
proteins called the myofilaments. These myofilaments are made up of bundles of thick
and thin filaments that form myofibrils; bundles of myofibrils form muscle fibers; and
finally, bundles of muscle fibers are skeletal muscle tissue. The thick myofilaments
contain myosin protein and thin myofilaments contain actin protein (Figure 1). The thin
and thick filaments, respectively, provide contractility to the cell and are spatially
arranged in regular and repetitive structures called the sarcomeres. The interaction of
these two myofibrillar proteins allows muscles to contract, and the mechanics of
contracture can be classified into fiber types based on different myosin structures
(isoforms) or physiologic capabilities (152). The three myosin isoforms that were
originally identified in humans were MHCI, MHCIIa, and MHCIIx/d, and they
corresponded to the isoforms identified by myosin ATPase staining as types I, IIA, and
IIX, respectively (125). In older literature what was originally identified in humans as
MHCIIb is actually MHCIIx/d, as humans do not express a fourth and fastest myosin
heavy chain isoform (MHCIIb) (65). Although rare, a fiber can have both the MHC I and
the MHC IIa isoform and is classified as a hybrid type I/IIa fiber. Similarly, some may
have MHC IIa and MHC IIx isoforms termed a hybrid type IIa/IIx fiber. (Table 1)
summarizes the properties of the three muscle fiber types found in human skeletal
muscle.
Muscle contracture occurs by a process called excitation contracture coupling (EC
Coupling), when the release of acetylcholine from the axon ending into the synaptic cleft
at the neuromuscular junction, initiates the depolarization of sarcolemma (muscle fiber
3

membrane), and leads to release of Ca2+ ions from the sarcoplasmic reticulum into the
sarcoplasm (cytoplasm). Ca2+ binds the troponin proteins found on the thin myofilaments,
initiating the attachment of actin to the binding site of myosin allowing the muscle
contraction process to occur, generating force. There are various molecular signals that
mediate skeletal muscle remodeling that will be discussed in the following sections.
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Pathways regulating skeletal muscle mass
Muscle atrophy involves the shrinkage of myofibers (decreased muscle fiber crosssectional area (mCSA)) due to a net loss of proteins partly related to upregulation of
degradation pathways, such as the ubiquitin-proteasome system. Recent studies have
shown these catabolic pathways modulate one another at different levels, and are coupled
to anabolic pathways. The result is a balance between protein breakdown and synthesis
that reflects the physiological state of the muscle fiber.
1.1.1

Protein breakdown
Muscle atrophy occurs with a change in the normal balance between protein

synthesis and protein degradation. The particular protein degradation pathway, which
seems to be responsible for much of the muscle loss seen in atrophy, is the ATPdependent ubiquitin-proteasome pathway. In muscle, the ubiquitin-proteasome system is
required to remove sarcomeric proteins in response to changes in muscle health (13, 26).
Skeletal muscle-specific ubiquitin E3 ligases Muscle RING finger 1 (MuRF1) and
muscle atrophy F-box (MAFbx)/atrogin-1 have been studied widely and play an essential
role during skeletal muscle atrophy (47, 105). This link is further supported by animal
studies in mice lacking atrogin-1/MAFbx and MuRF1 (15) that show both are needed for
atrophy, with other more recent studies showing MuRF1 not atrogin-1 knockout mice to
be resistant to dexamethasone-induced muscle atrophy (6). Additionally, MuRF1 has
been reported to interact with and control the half-life of important muscle structural
proteins such as myosin (25, 26, 43), suggesting that MuRF1 plays a dominant role in
various skeletal muscle atrophy conditions. It has also been reported that upregulation of
5

these proteins is time-dependent, with no changes in MuRF1 expression seen with a
prolonged catabolic stimulus (119). Forkhead box class O family member proteins
(FoxOs) are transcription factors that play important roles in regulating the expression of
genes involved in cell growth. Four FoxO members in humans, FoxO1, FoxO3, FoxO4,
and FoxO6, are all expressed in skeletal muscle, but FoxO1, FoxO3 members are the
most studied in muscle. FoxO1 and FoxO3 are key factors of muscle protein breakdown,
as the major transcription factors regulating both the MuRF1 and MAFbx expressions
(142, 153), with FoxO3a implicated as a major regulator in several disease states (1, 120,
182, 183). FoxO/MuRF1 signaling proteins are regulated on several fronts. In skeletal
muscle, the most studied post-translational modification of FoxOs is phosphorylation. 5'
adenosine monophosphate-activated protein kinase (AMPK) and Protein kinase B (PKB),
also known as (Akt) have opposite effects on FoxO3 localization and activity.
AMPK plays a role in cellular energy homeostasis when cellular energy is low it
phosphorylates FoxO3 at two regulatory sites (Ser-413/588) in skeletal muscle, leading to
its activation under stress conditions (115, 118, 140). Moreover, AMPK activation is
associated with increasing levels of FoxO1 and FoxO3 mRNAs and protein content
(118).
Akt is a serine/threonine protein kinase that plays a key role in insulin and
PI3K/Akt/mTOR signaling pathways, contributing to the regulation of energy
metabolism and protein synthesis. An essential regulator of FoxO activity, it inhibits
FoxO1, 3 and 4 by phosphorylation (Ser-253/315, Thr 32) under mitogenic activation
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(153) (Figure 2), preventing up-regulation of numerous ubiquitin–proteasome and
autophagy-related genes in muscle.
Another regulator of skeletal muscle atrophy is nuclear factor-kappaB (NF-κB),
which is a major regulator of gene transcription in response to oxidative, energetic, and
mechanical stress in skeletal muscle. Chronic activation of this signaling pathway has
been implicated in the development of various pathologies, such as cancer-related muscle
wasting. NF-κB transcription factors, which are expressed in skeletal muscle, mediate the
effect of inflammatory cytokines, particularly tumor necrosis factor-α (TNFα), on muscle
wasting (124). TNFα is thought to act via Mitogen-activated protein kinases (MAPKs) to
stimulate expression of the ubiquitin ligase atrogin1/MAFbx and MuRF1in skeletal
muscle (71, 89). Indeed, muscle-specific overexpression of NF-κB regulators in mice has
led to severe muscle wasting mediated, at least in part, by MuRF1activity (16, 101).
Other degradation pathways in skeletal muscle include the Ca2+-dependent
proteases, lysosomal system, and caspases, these pathways will not be covered in this
review. However, Akt regulates both the ubiquitin-proteasome system and the autophagylysosome pathway, and this action is mediated by FoxO transcription factors.

1.1.2

Protein synthesis
The growth of skeletal muscle mass, like the mass of any other tissue, depends on

protein turnover and cell turnover (143). Cellular turnover plays a major role during
muscle development in the embryo. Moreover, satellite cell incorporation into the
7

growing fibers takes place during postnatal muscle growth (110) simultaneously with
increased protein synthesis. However, the contribution of cellular turnover in adult fibers
is minor, and its role in hypertrophy has been recently debated (80, 96). In adult muscle,
the physiological conditions promoting muscle growth are mainly related to increasing
protein synthesis and decreasing protein degradation. However, satellite cells are
activated in compensatory hypertrophy (80, 110), and the addition of new nuclei to the
growing fiber seems to be required for extreme hypertrophy and therefore cannot be
completely discounted as a contributing mechanism. The pathways controlling cellular
and protein turnover are different, and their contribution to muscle hypertrophy has to be
considered.
Under normal physiological condition, the IGF-1-Akt-mTOR pathway is a key
regulator of protein synthesis in skeletal muscle (59, 145) with downstream of Akt that
include glycogen synthase kinase 3, the mammalian target of rapamycin (mTOR),
p70S6K, and PHAS-1 (4EBP-1), all key regulatory proteins involved in translation and
protein synthesis (56, 135). Changes in the Akt/mTOR and Akt/GSK3 pathways induced
skeletal myotube hypertrophy (135). Indeed, genetic models that overexpress or code
constitutively active forms Akt induced muscle fiber hypertrophy both in vivo (122) and
in vitro (83, 136). Knockout models of Akt display growth defects (133), and those in
which Akt and a related gene, Akt2, are both disrupted undergo skeletal muscle atrophy
(137).
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1.1.3

Skeletal muscle mitochondrial homeostasis
Several metabolic adaptations occur in atrophying muscles. In many forms of

muscle wasting, expression of a variety of enzymes important for oxidative
phosphorylation is suppressed (29). Dysfunctional mitochondria, in particular, are
thought to play a key role in muscle function decline, as the mitochondria are the main
producers of both cellular energy and free radicals. Mitochondrial dysfunction has been
tightly associated with excess production of reactive oxygen species (ROS) (97).
Chronically elevated ROS can initiate DNA damage, protein oxidation, increased
oxidative damage and reduced oxidative capacity. These biochemical changes are
accompanied by changes in skeletal muscle dynamics, such as a decrease in
mitochondrial biogenesis and an increase in autophagy/mitophagy (Figure 3).
Mitochondria are dynamic, existing in networks that are constantly being remodeled by
biogenesis, fusion and fission, and degradative processes.
Recent studies have shown that PGC-1α, the master regulatory gene for
mitochondrial biogenesis, is downregulated in different models of muscle wasting (74).
Indeed, when the levels of PGC-1α are maintained, either by the use of transgenic mice
or by transfecting adult muscle fibers, muscles are protected from the atrophy induced by
denervation, fasting, or expression of FoxO3 (74, 75, 165). PGC-1α is triggered when the
energy demand exceeds respiratory capacity, in response to exercise, stress, and ROS
production (66). PGC-1 also activates the nuclear respiratory factors 2 (Nrf-2) (76),
thereby driving the transcription of other proteins that are linked with mitochondrial
health and skeletal muscle homeostasis via the regulation of ROS (79). Excessive
9

mitochondrial ROS are associated with oxidative damage and disease states (150, 167).
This is supported by studies that utilize mitochondria-targeted antioxidants that have been
shown to be beneficial against skeletal muscle atrophy and mitochondrial dysfunction
(17, 104).

10

Regulators of cancer related skeletal muscle wasting
1.1.4

Tumor Factors
For the last seven decades, there have been attempts to identify and understand

what secreted factors from tumors signal skeletal muscle atrophy. In this search, various
cytokines and catabolic factors that could regulate the loss of skeletal muscle mass have
been identified (108, 112). These pro-inflammatory and pro-catabolic factors are thought
to be produced by the tumor cells and have important roles in the development of cancerrelated atrophy. For instance, pro-inflammatory cytokines, such as tumor necrosis factor
alpha (TNF)-α, interleukin (IL)-1, IL-6, and anti-inflammatory cytokine such as IL-10,
promote the activation of factors associated with muscle wasting. These factors cooperate
with each other or act alone as drivers of systemic inflammation. The molecular
mechanisms by which these pro-inflammatory factors may contribute to the development
of skeletal muscle atrophy have been linked to the activation of various downstream
molecules in muscle and fat.
1.1.4.1 Increase Protein break down
TNF-α has been reported to be upregulated in several forms of cancer (46, 48)
and is linked to the catabolism of various myofibrillar proteins in the myotubes via
activation of nuclear transcription factor-kappaB (NF-κB) through IkB kinase signaling
(71). The activated NF-κB increases the transcription of genes such as MuRF1 that
specifically degrades myofibrillar proteins such as myosin, contributing to the loss of
lean body mass during cancer-related atrophy (23, 30, 95). Similarly, IL-6 induces
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apoptosis in skeletal muscles by increased caspase activity via activation MAPK cascades
(61, 159).
1.1.4.2 Reduce protein synthesis
Along with the TNF-α and IL-6, recent preclinical studies in murine models of
cancer-related muscle wasting demonstrated that higher levels of IL-10 inhibited protein
synthesis in skeletal muscles via increased levels of Myc and activation of mTOR
signaling (4, 134). This link to cancer-related muscle wasting is predominantly based on
the concept of tumors reprograming host metabolism (44).
Metabolic reprogramming has been linked with proteolysis-inducing factor (PIF)
which acts by decreasing protein synthesis through phosphorylation of eukaryotic
translation initiation factor 2α and accelerating protein degradation through the ubiquitinproteasome pathway promoting skeletal muscle atrophy (160, 166). In addition to proinflammatory cytokines, myostatin is another muscle-wasting factor that is secreted by
the skeletal muscles, adipose tissue, and tumor cells (60, 149, 178). Myostatin acts via
activin receptor type II-mediated signaling and regulates muscle wasting (37, 109, 161).
Further to the pro-inflammatory and atrophic factors, cancer-related muscle wasting is
associated with other host factors such as neuroendocrine stress responses via the release
of glucocorticoids (158, 163). Though the muscle cells and nervous system crosstalk is
not fully elucidated, it is thought that this mechanism is complex, and further studies are
needed to understand the role of pituitary hormones in inducing muscle wasting and
lipolysis.
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1.1.5

Chemotherapy
Chemotherapy treatments are a combination of drugs administered in a

standardized treatment regimen, specific for the cancer type. Various interactive effects
of different drugs could occur; leading to numerous deleterious consequences to normal
tissues, including pulmonary toxicity, myotoxicity, mitotoxicity, and cardiotoxicity. How
these various compounds may induce atrophy in cancer patients is poorly characterized,
and the breadth of literature on the topic is significantly less than tumor factors. However,
the direct effects of systemically administered chemotherapeutic agents, which circulate
to all tissues in the blood, are prime candidates. Non-tumor tissues, including skeletal
muscle, are exposed to a variety of chemotherapy-related toxic effects over the course of
treatment with most standard chemotherapy regimens. These include repeated cycles of
acute exposure to high levels of oxidative stress (24) which disrupt a wide range of
cellular functions.
1.1.5.1 Doxorubicin
Anthracyclines such as doxorubicin are thought to produce their biologic activity
principally via interaction with topoisomerase II and subsequent double-stranded DNA
breaks (28, 68, 155), however, defects in mitochondrial biogenesis and the production of
reactive oxygen (68, 155) has been reported in several studies. Muscle toxicity of
anthracyclines is mediated through increased production of reactive oxygen species
(ROS) by muscle mitochondria and increased catabolic processes that upregulate
MuRF1and impair contractile function (77, 179).
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Different tissues accumulate anthracycline-induced mitochondrial damage at
varying rates, in rats defective mitochondrial respiratory enzyme activity and increased
ROS production are observed in renal (86) tissues, 6–7 months after the end of treatment.
Existing studies in tissue culture, rodents, and humans show acute negative effects of
anthracyclines such as doxorubicin on skeletal muscle. Administration of doxorubicin
induces skeletal muscle mitochondrial ROS, increases proteolysis and leads to muscle
weakness (53-55). Direct injection of doxorubicin into skeletal muscle causes atrophy,
and altered myofilament structure humans and rodents (98, 172).
Cardiac toxicity is also a well-known side effect of anthracycline chemotherapy
and has been the subject of numerous investigations (85), showing that this cardiotoxicity
is increased with higher cumulative doses (40). Cardiotoxicity is a dose-limiting side
effect of doxorubicin (22).
1.1.5.2 Cisplatin
Cisplatin is a platinum-based anti-cancer drug common in breast, and lung cancers (35),
and is thought to interfere with DNA replication, targeting the fastest proliferating cells.
It has a number of side effects that can limit its use to include nephrotoxicity and
neurotoxicity, with the former being a dose-limiting side effect (103). The mechanisms
by which cisplatin affects skeletal muscle, however, are less well described. Cisplatin
produces significant muscle atrophy in mice, via the activation of NF-κB; however, other
studies have demonstrated that F-box, MuRF1, and FoxO3 are significantly increased
with cisplatin treatment (138, 175). These increases of catabolic markers have also been
linked to transient and acute reduction of protein synthesis in both healthy and tumor14

bearing mice (139). Both these types of cellular toxicity are potentially relevant in
initiating changes in muscle tissue which lead to the long-term functional deficits.
1.1.5.3 Paclitaxel
Taxane drugs, such as paclitaxel and docetaxel, are chemotherapeutic agents, which work
by disrupting microtubule function to inhibit cell division. Taxanes have become a
common agent primarily against breast cancer, metastatic prostate cancer, and non-small
cell lung cancer due to its efficacy in solid tumors. These drugs are believed to induce
sensory and motor neuropathy by impairing axon structure and function, most
specifically by inducing mitochondrial and vascular dysfunction (127). Other side effects
of taxane treatment are pain in the joints and muscles, occurring 2 to 3 days after
paclitaxel treatment (52). There are currently no comprehensive studies looking at the
mechanisms for which paclitaxel or other taxanes may induce skeletal muscle atrophy.
However, studies have looked at the consequences of impairing microtubule dynamics in
skeletal muscle. The microtubule cytoskeleton in skeletal muscle resists mechanical
perturbation acting as a mechanotransducer (27, 151) allowing the cell to respond
mechanically to the environment. Animal studies have shown that disrupting the tubulin
dynamics with paclitaxel in skeletal muscle increases cellular ROS and oxidasedependent production of ROS (78). Indeed tubulin has been implicated regulating
mitochondrial bioenergetics and that paclitaxel treatment impaired mitochondrial
ADP/ATP exchange resulting in greater H2O2 emission kinetics.
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1.1.5.4 Glucocorticoids
Drugs such as dexamethasone and prednisone are frequently used for their anti-emetic
properties around the time of chemotherapy (90, 116, 148). During the administration of
glucocorticoids, especially prolonged courses or higher doses, skeletal muscle atrophy
can be expected (8, 14). Additionally, glucocorticoid treatment-related myopathy is
reported to be more pronounced in proximal muscles and fast twitch (type II) fibers
(144). There is still research as to whether high dose glucocorticoids contribute to longterm muscle dysfunction, there is evidence that prolonged corticosteroid use can induce
muscle mitochondrial dysfunction and increased oxidative damage to both nuclear and
mtDNA (106).
1.1.5.5 Other chemotherapies
Other chemotherapy drugs have also been associated with skeletal muscle
dysfunction, but evidence of a direct effect on skeletal muscle is currently less
characterized than the agents discussed above (35, 70). However, there is not yet enough
clinical follow-up data to know whether these newer drugs also have deleterious longterm impacts on skeletal muscle or other tissues. Thus, it remains possible that the
specific agents discussed above, used in the treatment of cancer have a synergistic impact
on muscle, distinguishing the role of each drug in causing muscle dysfunction in an in
vivo setting is extremely challenging. Nevertheless, models to help elucidate these
mechanisms are being utilized.
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With the current treatment regimens leading to higher cancer survival rates, we can
anticipate that these agents will continue to be used, increasing the number of cancer
survivors. Deficits in skeletal muscle and function have been reported to persist many
years after successful treatment (19, 176), implicating anti-cancer treatments themselves
as the likely cause of long-term muscle dysfunction.

17

Exercise
Although cancer treatments, such as chemotherapy, can be efficacious, they can
lead to long-term side effects such as fatigue, muscle loss, and reductions in functional
capacity (31). However, currently, there are no effective treatments specifically targeting
cancer related skeletal muscle atrophy. Cancer-related muscle atrophy is a multi-factorial
syndrome that may require an approach that targets the different factors involved.
Historically, clinical interventions and studies have focused on stabilizing and improving
the nutritional status, finding novel biomarkers, and developing better techniques for the
estimation of muscle mass. However, there is new interest in exercise training and muscle
loss prevention in cancer patients (100, 128, 171). Exercise training has an important role
in skeletal muscle plasticity, acting on several pathways and possessing multifactorial
effects. Within the muscle, it has anabolic and catabolic effects, it exerts antiinflammatory effects, and it has anti-oxidative implications (88).
1.1.6

Exercise-related mechanisms

For a skeletal muscle to undergo exercise-specific adaptations, it must both sense and
transmit the information that is unique to each type of exercise stimulus. The force
generated in sarcomeres is transferred to the extracellular matrix via focal adhesions,
where the actin cytoskeleton is connected via linker proteins to the extracellular-matrixbound trans-membranous integrins (Figure 5). Changes in mechanical stress are
responsible for changes in the multiprotein complexes called costameres in skeletal
muscle involved in mechanotransduction and mechano-sensing (167). The transmission
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of this information is mediated by signaling pathways that rely on the use of reversible
posttranslational modifications to transmit information. Physiological stressors that are
active during exercise have been identified: mechanical load, neuronal activation,
hormonal adjustments and metabolic disturbances (45). During exercise at a specific
intensity and over a defined period of time, muscle tissue experiences a particular blend
of these fundamental stressors (63). With strength training, the mechanical stress is
dominant, while during endurance exercise, mechanical stress is low but metabolic
disturbances can protract. A single bout of physical activity/exercise induces muscle
molecular signaling pathways linked to anabolic/catabolic processes that have
documented effects on muscle health. Furthermore, repeated bouts of activity can
stimulate beneficial mechanical adaptations (102). These acute responses and chronic
adaptations to exercise have utility for improving muscle function (62).
In healthy groups, a single bout of exercise mechanical stress can stimulate
protein synthesis, which remains elevated for several hours following contraction (34).
The duration and extent of this induction can be affected by exercise type (endurance vs
resistance), intensity and workload of muscle, but have been shown to induce signaling
through extracellular regulated kinase, stress-activated protein kinase and protein kinase
such as Akt, and ribosomal S6 kinase (3, 38, 170, 173). In preclinical studies, the ability
of muscle contraction to induce protein synthesis has implications for cancer-related
muscle wasting in which Akt/mTORC1 signaling may be disrupted (169). Skeletal
muscle mass depends on mechanical stresses induced during specific exercise types.
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Acute exercise can accelerate protein turnover and may serve to replace damaged
proteins, which is necessary for the maintenance of muscle homeostasis. Repeated
exercise training can decrease the indices of protein breakdown in muscle, which may be
related to improved protein quality (16). Additionally, muscle protein breakdown is
stimulated by both acute endurance and resistance exercise (162, 174) related to the need
to clear damaged proteins induced by contraction or mechanical loading. Protein turnover
and homeostasis have been shown in animal models were voluntary running decreased
Murf1 expression and autophagy protein expression when induced via catabolic
compounds (126).
Muscle oxidative metabolism is also modified with acute and repeated exercise,
expression of several mitochondrial proteins such as PGC-1α, and Nrf (57) have been
reported. Evidence also suggests that resistance exercise can improve mitochondrial
quality and function via mTORC1 inducing muscle PGC-1α protein expression (33)
increasing mitochondrial gene expression and oxidative function (181). Endurance
exercise can also positively regulate mitochondrial dynamics through modification of
fusion and fission protein expression (36). Damaged or dysfunctional mitochondria
removal has also been identified as an important exercise benefit (180).
1.1.7

Neuromuscular electrical stimulation
Exercise is not always possible due to treatment complications or

contraindications to aerobic exercise and resistive training. Reports suggest that only
~ 35% of cancer survivors achieve current recommendations (94, 154) with
breathlessness, fatigue, weakness, and poor balance cited as common issues affecting
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basic exercise participation such as walking (92). Thus, pragmatic alternatives to
traditional exercise methods are required.
Neuromuscular electrical stimulation (NMES) involves controlled muscular
contractions generated by electrical impulses delivered through surface electrodes,
usually placed on major muscle groups such as the quadriceps and hamstrings (69). The
evoked contractions have proven efficacy in improving muscle strength and
cardiorespiratory fitness across a variety of populations (9, 20, 21, 32). Thus, physiciansupervised NMES exercise to enhance the neuromuscular systems has applicability
within the cancer population to prevent the complications associated with treatment and
improve health-related quality of life. However, NMES uptake clinically is low (93) and
currently, no published, high-level evidence supports its application in cancer
survivorship. Although experimental evidence in different populations highlights the
efficacy of NMES, there is a need to evaluate the efficacy in cancer patients and cancer
survivors before it can be implemented into cancer care pathways. Previous work in
NMES and cancer has focused on tetanic, muscle strengthening protocols, nonetheless,
the mechanisms that lead to the reported beneficial effects of NMES is poorly
characterized, leaving a gap in the field that needs to be filled.
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Models
Although atrophy is a common outcome of experimental and human cancer cachexia,
discrepancies in the mechanisms underlying cancer-related muscle wasting have been
reported between different experimental models as well as in patients with different
tumor types, with limited available data in humans (71, 111). These differences in
experimental design and clinical outcomes hinders the development of therapeutic
strategies and underscore the need for more research on patients and the development of
pre-clinical models that closely emulate the clinical scenario (123). Currently, most
clinical trials on cancer-related atrophy have been conducted in patients very advanced in
their disease trajectory, or in animal models with exaggerated clinical phenotypes lacking
physiological relevance. This leads to speculation that some reported outcomes are an
artifact of experimental design or limited clinical evaluation (130). Using a simplified
system such as a cell line offers advantages in experimental design such as consistency,
availability, robust cell growth, and simple manipulation. There is the caveat that
immortalized cell lines often have been cultured for very long periods of time, which may
lead to changes in normal function. However, these deviations are limited and can be
mitigated with proper controls, with the additional advantages of reducing animals use
and easy transfection. Another option for cell culture is the use of primary human skeletal
cells, however; there are several issues that need to be considered. With primary skeletal
muscle cells, the amount and source of the tissue can vary, leading to varying results in
mechanical and biochemical results depending on the fiber types, there is also the limited
passage capacity of primary cells, and the difficulty in keeping a primary line going.
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However, the commercially available mouse-derived muscle cell line C2C12 is
frequently used to study intracellular signaling and function in skeletal muscle cells.
1.1.8

C2C12 model
The immortalized cell line designated C2C12 were generated by Blau, Chiu, and

Webster (11) as a subclone of the C2 cell line isolated by Yaffe and Saxel at the
Weizmann Institute of Science in Israel in 1977 (177). C2C12 cells were originally
derived from satellite cells from the thigh muscle of 2-month old female C3H dystrophic
mice 70 h after a crush injury. The C2C12 cell line differentiates rapidly, forming
contractile myotubes and producing characteristic muscle proteins. These proteins
include slow- and fast-twitch skeletal muscle myosin isoforms (132) with fast myosin
Type IIx the most dominant isoform (18, 146), along with other important sarcomeric
proteins involved with contracture (121, 168). These cells have similar characteristics to
those of isolated human skeletal muscle cells (51, 87, 91), and have been utilized in
several experiments as a model of contraction.
C2C12 cells are capable of rapid proliferation under high serum conditions and
can later fuse to form multinucleated myotubes under low serum conditions or starvation,
leading to the precursors of contractile skeletal muscle cells in the process of myogenesis
(12). Myogenesis in C2C12 can be controlled by genetic manipulation, making it a
powerful system for studying muscle development (10). The molecular regulators of
myogenic differentiation in C2C12 including the paired box transcription factors Pax7
and the myogenic regulatory factors Myf5, MyoD, myogenin (49, 81), that have been
used as early markers of differentiation and maturity in myotubes. Studies have shown
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that within two days of differentiation, the normal cells form spindle-shaped
mononucleated myoblasts that are in the process of cell migration and fusion (168). By 45 days, multinucleated myotube networks formed and some ultrastructure such as
unorganized precursor to sarcomeres are visible (82). By 6-8 days sarcomeres and Z-lines
could be observed (168) the myofibril content appear to be increased, and the sarcomeres
are present across the width of myotubes (Figure 4) (99). By this point in their
development C2C12 cells demonstrate maturation into functional muscle having the
ability to contract and generate force (99).
C2C12 in vitro cells are also a great model for testing physiological stresses,
determining their relevance and functions to humans (73). Through literature review, it
was found that the most effective functional assay, due to their differentiation and
contractile dynamics, is their response to electrical stimulation, since C2C12 myotubes
when mature express calcium ion channels and are able to trigger the
contraction/relaxation cycle at various voltages (58). These known characteristics of the
C2C12 make it a viable cell line to test the effects of exercise/NMES against various
catabolic environments present during cancer-related atrophy.
1.1.9

Electrical stimulation in a model system
C2C12 myotubes can grow on various surfaces when appropriate matrix proteins

are in place and electrically stimulated with commercially available carbon electrodes
(50, 117). This system is easy to manipulate and is useful for analyzing the biochemical
and molecular biological phenomena induced by muscle contraction. However, there are
fundamental differences between physiological contractions and those evoked by some in
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vitro STIM protocols. During exercise, muscle contractions are generated due to the
activation of motor units by action potentials. Moreover, the frequency is modulated to
match the requested power output, and the motor units in a contracting muscle are not
simultaneous but alternately activated (107), making it difficult to estimate the duration
of each stimulus. It is difficult to evaluate which STIM protocol mimics more an
endurance-type or resistance-type in vivo exercise. An approach to overcome the
limitation of an undefined STIM protocol was presented by Sciancalepore et al. who
recorded electromyographs of human gastrocnemius medialis during activity (147) and
then applied this stochastic STIM pattern to primary myotubes with varied results. As
novel as this approach was most current STIM studies have used two different
approaches of either high-frequency protocols with rest periods in-between short pulses
or with a constant frequency over several hours up to 48 h without resting period (157).
Either of which does not accurately reflect the in vivo conditions patient muscles are
exposed to during exercise but do emulate extreme weight lifting or ultra-long distance
running. Others have applied more exercise relevant STIM methodology of low volts and
frequency for 30- 60 minutes (72, 114) however, most have not applied it over a multiday period, providing only acute results. A STIM protocol that could be implemented
over several days, to test the chronic effects of exercise, and best emulate in vivo exercise
conditions was lacking in the literature, and development of one was needed for future
studies.
With all the controls in place, there are still limitations to an in vitro STIM
system, blood flow, and innervation, which are important for feedback regulations to
meet the metabolic demands of working muscle in vivo cannot be emulated in vitro. In
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addition, muscle fibers in vivo are in a 3D environment surrounded by connective tissue
and extracellular matrix, which might affect transcriptional activation of genes in
contracting cells, as well as protein release (39) which are difficult to replicate in vitro, as
the exact substrate demand of myotubes subjected to STIM is unknown. Moreover, In
vivo skeletal muscle is also connected to the skeleton via tendons, and during
contractions, the mechanical load is applied to the myofibers. Using inappropriate
conditions or too long stimulation might result in detachment of myotubes, compromised
cellular integrity, and damage of cells, as outlined above. Although cultured myotubes
are attached to the surface of the culture dish during STIM, the mechanical load is not
comparable nevertheless, cell culture allows for the standardization of all these conditions
allotting for reproducibility. Finally, some side effects of STIM have to be considered, in
particular when long-term stimulation is performed.
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Conclusion
Although the factors that lead to cancer-related muscle wasting are still debated, the
current paradigm is focused on the pathophysiological state of anabolism and catabolism
dysregulation, with decreased protein synthesis and increased MuRF1 expression.
Physical activity and exercise are already thought to be beneficial during cancer treatment
and holds clear potential as a nonpharmacological treatment for muscle wasting
conditions. Emerging evidence from preclinical models suggests an interaction between
increased physical activity/exercise and improvements in muscle mass and mitochondrial
function, possibly mediated via the contracture of muscle. However, the complexity of
etiology and the manifestation of the symptoms will likely need a multimodal format
approach to treatment. Further research is warranted to determine the mechanistic basis
of these improvements and if these benefits can be achieved with surrogates of exercise
such as with NMES.
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Figures
FIGURE 1:

Figure 1.0.1: Skeletal muscle structure
Structure of skeletal muscle (From: Raven et al. Fig. 3.6) (131)
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FIGURE 2:

Figure 1.0.2: Skeletal muscle Akt pathway.
Scheme illustrating the regulation of FoxO via modulation of ROS and the Akt
pathway. (From: Sandri et al. Fig. 3) (141)
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FIGURE 3:

Figure 1.0.3: Mitochondrial dynamics schematic.
Mitochondrial regulation in skeletal muscle (From: Hood et al. Fig. 1) (67)
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FIGURE 4:

Figure 1.0.4: light microscope image of mature C2C12 myotube
C2C12 myotube, 8 days post starvation, photographed in culture. Striations suggest
presence of well-organized myofilaments. (From: McMahon et al. Fig. 1A)(99)
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FIGURE 5:

Figure 1.0.5: Schematic representation of the intermediate
filament in skeletal muscle.
Schematic representation of the intermediate filament (IF) scaffold in
striated muscle. The IF scaffold, predominantly composed of desmin
(yellow), links the entire contractile apparatus to the sarcolemma and
other organelles, such as the nucleus, mitochondria, lysosomes, and
potentially the sarcoplasmic reticulum (SR). Desmin interacts with
many other proteins including synemin, paranemin, syncoilin, and
myospryn. Keratins (K8/K19) link the contractile apparatus to the
sarcolemma and interact with the dystrophin-dystroglycan (DG)
complex. Overall, the IF scaffold helps maintain the integrity of
muscle cytoarchitecture and provide mechanical strength to the cell.
Abbreviations: MLP, striated muscle-specific LIM protein; SG,
sarcoglycan, From: Henderson et al. Fig. 3) (64)
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Table 1.1: Common properties of skeletal muscle fiber types
Type I
Other Names
Metabolism
Myosin Heavy Chain
mATPase activity
Power
Velocity
Force
Mitochondrial density
Endurance capacity
Appearance

Slow Twitch
Oxidative
MHC I
Slow
Weak
Slow
Low
High
High
Red

Type IIA

Type IIX
Fast
Fast Twitch
Twitch
Oxidative/Glycolytic Glycolytic
MHC IIa
MHC IIx
Fast
Very fast
Intermediate
Strong
Fast
Very fast
Intermediate
High
Intermediate
Low
Intermediate
Low
Pink
White
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List of abbreviations
2-[4-(2-hydroxyethyl) piperazin-1-yl]ethanesulfonic acid
Antioxidant response element
atrogin-1/muscle atrophy F-box
Autophagy Lysosome Pathway
circulating Atrophy Inducing Factor
c-Jun N-terminal kinase
Conditioned Medium
Cross Sectional Area
Dimethyl sulfoxide
Dithiothreitol
Doxorubicin
Dulbecco´s Modified Eagle´s Medium
Electron Microscopy
extracellular signal-regulated kinase 1/2
Fetal Bovine Serum
GABA(A) receptor-associated protein-like 1
glutathione
Hank’s balanced salt solution
Human biopsy cell line
Interleukin 6
Kirsten rat sarcoma viral oncogene homolog
Lewis lung carcinoma
Lox-Stop-Lox- KRASG12D
Manganese superoxide dismutase
mitogen-activated protein kinase
Mouse tracheal epithelial cell
Muscle-specific RING finger protein 1
Myosin Heavy Chain type I
Myosin Heavy Chain type II
N-acetylcysteine
Nicotinamide adenine dinucleotide phosphate
non-small cell lung
non-small cell lung cancer
Nuclear factor (erythroid-derived 2)-like 2
nuclear transcription factor kappa B
Paclitaxel
Penicillin-Streptomycin
Peroxiredoxin 3
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HEPES
ARE
MAFbx
ALP
cAIF
JNK
CM
CSA
DMSO
DTT
DOX
DMEM
EM
ERK1/2
FBS
Gabarapl1
GSH
HBSS
hTCM
IL-6
KRAS
LLC
LSL-KRASG12D
MnSOD
MAPK
MTEC
MuRF1
MHC I
MHC II
NAC
NADPH
NSCL
NSCLC
Nrf2
NFκB
TAXOL
P/S
Prx 3

Peroxisome proliferator-activated receptor gamma
coactivator 1-alpha
Phosphate Buffered Saline
phosphatidylinositol 3-kinase (PI3-kinase)/protein kinase B
Proteolysis Inducing Factor
quality of life
Quantitative real time PCR
Reactive oxygen species
sarcoplasmic reticulum
small cell lung cancer
small interfering RNA
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
superoxide dismutase
TBS-Tween
TNF receptor subtype 1
Tris-buffered saline
tumor necrosis factor-alpha
Tumor Necrosis Factor-α
Ubiquitin 26S-Proteasome System
Whole Cell Lysate
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PGC-1α
PBS
Akt
PIF
QOL
qRT-PCR/qPCR
ROS
SR
SCLC
siRNA
SDS PAGE
SOD
TBST
TNFR1
TBS
TNF
TNFα
UPS
WCL
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Abstract
Tumor-secreted factors are hypothesized to cause fat and skeletal muscle wasting in
cancer patients. To test this hypothesis, we examined whether tumor cells secrete factors
to promote atrophy by evaluating the effects of tumor-conditioned media (CM) from
murine and human lung tumor cells on cultured muscle myotubes. We evaluated two
murine lung cancer cell lines that produce cachexia in mice, Lewis lung carcinoma (LLC)
and KRASG12D cells, and primary cell lines derived from tumor biopsies from patients
with lung cancer (hTCM; n=4). We hypothesized that conditioned media from murine
and human tumor cells would reduce myotube myosin content, decrease mitochondrial
content and increase mitochondrial reactive oxygen species production (ROS). Treatment
of myotubes differentiated for 7 days with CM from LLC and KRASG12D cells did not
alter myotube myosin content or mitochondrial content or ROS production. Effects of
murine tumor cell CM were observed, however, when myotubes differentiated for 4 days
were treated with tumor cell CM and compared to undiluted differentiation media.
However, these effects were not apparent if tumor cell CM treatments were compared to
control cell CM or dilution controls. Finally, CM from human lung tumor primary cell
lines did not modify myosin content or mitochondrial content or ROS production
compared to either undiluted differentiated media, control cell CM or dilution controls.
Collectively, our results argue against the hypothesis that lung cancer cell-derived factors
act directly on skeletal muscle to promote muscle wasting or mitochondrial
abnormalities.
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Introduction
Cancer cachexia is a syndrome characterized by unintentional loss of both fat and
skeletal muscle tissue (19) that affects ~50% of patients (18, 60). Patients with solid
tumors are most likely to experience muscle atrophy, particularly in advanced stages (42).
Muscle wasting increases treatments side effects (15, 23, 55), decrease response to
chemotherapy (29, 33, 53) and increases mortality (17). Despite these deleterious
consequences, the causes of cancer cachexia remain unclear.
How tumors that are anatomically distal to skeletal muscle cause atrophy is
unknown. One long-standing theory holds that factors released from tumor cells promote
tissue wasting, through direct effects on the muscle or indirectly by provoking hostrelated factors, such as inflammatory cytokines. Data supporting this theory comes
primarily from pre-clinical models (2, 37, 47). While these studies have provided a
wealth of mechanistic data, their translatability to human cancer remains questionable. In
animal models, tumors grow rapidly and comprise a large fraction of body mass (7). For
instance, in the C26 xenoplant model, the onset of cachexia typically occurs when the
tumor reaches ~5% of body mass (56), which occurs 2-4 weeks after inoculation (10, 30).
Extrapolated to humans, the size of this tumor would equate to an ~8 lb. tumor in men
and ~6 lb. tumor in women. Accordingly, the pathoetiology of cachexia in these preclinical models may be skewed disproportionately towards tumor-derived factors. In
contrast, human tumors develop relatively slower and comprise <<1% of body mass. In
this context, cancer cachexia in humans may be less dependent on tumor-derived factors
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and/or factors derived from tumor cells may be less effective at promoting muscle
wasting and cachexia.
A common model for testing the effect of tumor-derived factors on skeletal
muscle involves treating cultured muscle cells with conditioned media (CM) from tumor
cells (11, 21, 52, 58, 59). Conditioned media experiments provide a more focused model
to examine the direct effects of tumor-derived factors on skeletal muscle. Data from these
approaches using various cell lines support the notion that tumor-derived factors promote
skeletal muscle atrophy (38, 63, 64, 69). In the current study, we sought to use this model
to examine the effects of lung cancer cell-derived factors on skeletal muscle. We chose
lung cancer because these patients experience a high prevalence of cachexia (6) and
because lung cancer is a common model used for pre-clinical cancer cachexia studies. We
utilized CM from two murine lung tumor cell lines: the Lewis lung carcinoma (LLC) and
KRASG12D cell lines. The former potently induces cachexia in mice (48, 69) and is used
widely in the field. The latter contains the most frequently occurring mutation in human
non-small cell lung tumors (62) and provides a near genetically identical cell line for
control studies. Additionally, we report, for the first time to our knowledge, the effects of
CM from primary cell lines derived from clinical biopsies of human lung tumors. We
tested the effects of CM from these cells on differentiated C2C12 myotubes. Myotubes
were differentiated for 7 days prior to treatment with CM, a time when they develop
anatomical and physiological attributes similar to in vivo skeletal muscle and demonstrate
atrophy in response to myotoxic chemotherapeutics, such as anthracyclines (24). Based
on prior work in the field using these and other cell lines, we hypothesized that CM from
murine and human tumor cells would reduce myotube myosin content, decrease
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mitochondrial content and increase mitochondrial reactive oxygen species production
(ROS).
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Methods
Cell culture
C2C12 myoblasts (ATCC® CRL-1772™, Manassas, VA) were cultured in low glucose
(1 g/L), Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS; Gibco™ Thermo Fisher Scientific Waltham, MA) and antibiotics
(50 U/ml penicillin and 50 μg/ml streptomycin). Cells were plated (2 X 104 cells/cm2) on
Matrigel (60 μg/cm2; Corning, Bedford, MA) and switched to differentiation media (DM)
of low serum (1% heat-inactivated FBS), high glucose (4.5 g/L) DMEM when they
reached 90-100% confluence to induce differentiation, as described (32).
Lewis lung carcinoma (LLC; ATCC CRL-1642) cells, a murine lung cancer cell line that
promotes cachexia in mice (46), were cultured, as described (21). Briefly, 2 X 105 LLC
cells were plated on 10-cm diameter culture dishes in DMEM, supplemented with 10%
FBS, 50 U/ml penicillin and 50 μg/ml streptomycin, and grown for 48 h to a final density
of 0.8–11 X 106 cells per culture dish. NL20 (ATCC CRL-2503) cells were used as a
control cell line for LLC cells, as they are non-tumorigenic and have been used as
controls for LLC CM treatment of C2C12 myotubes previously (70). NL20 cells were
grown, as described (21). Briefly, 2 X 105 NL20 cells were plated into 10-cm diameter
culture dishes in DMEM, supplemented with 10% FBS, 50 U/ml penicillin, and 50 μg/ml
streptomycin, and grown for 48 h to a final density of 0.8–11 X 106 cells per dish. For
both LLC and NL20 cells, CM from this 48 hr growth period was collected, centrifuged
to remove cell debris and stored at -80°C until use.
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Primary mouse tracheal epithelial cells (MTECs) were isolated from 14 week old male
and female LSL-KRASG12D (The Jackson Laboratory #008179), as described (28). The
LSL-KRASG12D mice were generated by crossing CCSP-rtTA (The Jacksons Laboratory
CCSP-rtTA #006222) and TetO7-Cre (The Jacksons Laboratory #006224) bi-transgenic
mice, to create CCSP-rtTA/TetO-Cre/LSL-KRASG12D mice, as described (1). Cells were
cultured on collagen-coated plates in DMEM/F12 media containing 10 μg/ml cholera
toxin (Sigma), 2 mg/ml insulin (Roche), 2.5 mg/ml transferrin (Sigma), 12.5 mg/ml
bovine pituitary extract (Invitrogen), 10 μg/ml epithelial growth factor (Calbiochem), 50
μM dexamethasone (Sigma), U/50 μg/ml p/s (Gibco), 4.5 mM L-glutamine (Invitrogen),
and 1 ml Primocin (InvivoGen), as described (1). MTECs were either treated with a Cre
recombinant adenovirus to activate the oncogenic KRAS mutation (KrasG12D) or an
empty vector (KrasWT), which serves as a control cell line. Cells were then washed and
cultured in serum free media for 2 days and the media was collected, centrifuged to
remove cell debris and stored at -80°C until use.
To obtain human tumor cell CM, lung tumor cells obtained from patients during clinical
evaluations were used to establish primary cultures, as described (43), with
modifications. Briefly, tissue obtained from the biopsy was treated with elastase and
DNAse, and then cultured in RPMI 1640 supplemented with L-glutamine and HEPES on
collagen-coated dishes. Primary broncheal/tracheal endothelial cells (HBEC; ATCC,
PCS-300-010) (2.5 × 10^5 cells/cm2) were used as a non-cancer cell line. They were
cultured as adherent monolayers in minimum essential media (MEM) (Invitrogen;
Carlsbad, CA) supplemented with 9% FBS (Invitrogen), 2 mM L-glutamine, 100 U
penicillin and 100 μg/mL streptomycin (Sigma-Aldrich; St. Louis, MO). For both
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primary tumor and HBEC cells, CM was collected following 24 hr incubation in RPMI
1640 + 9% FBS, centrifuged to remove cell debris and stored at -80°C until use.
Preparation of CM and HBSS dilution control.
One volume of tumor or control cell CM was mixed with three volumes of serum-free
DMEM to treat myotubes. In all cases, serum content was standardized so that both CM
diluted and undiluted DM treatments had the same final serum concentration (2.5% for
LLC and NL20 cells; 1% for KrasG12D and KrasWT cells and 2.25% for human tumor and
HBEC cells). We also included a dilution control to our experiments, which consisted of
DM diluted 1:3 with Hank’s balanced salt solution (HBSS; 1 g/L glucose). Thus, we have
4 treatment groups in each experiment: untreated controls (undiluted DM; i.e., no CM
added), dilution control (1:3 dilution of HBSS:DM), non-tumorigenic/cachectic cell CM
control (1:3 dilution of CM:DM) and tumor cell CM (1:3 dilution of CM:DM). In all
conditions, media was changed daily during the 3-day treatment period.
Patients
Patients (76 ± 7 yr; Table 1 for details) with known or suspected lung cancer were
recruited from the University of Vermont Medical Center Lung Multi-disciplinary Clinic.
Written informed consent was obtained from all volunteers prior to their participation and
protocols were approved by the Committees on Human Research at the University of
Vermont. Tumor cells were obtained when patients underwent either clinically indicated
bronchoscopy or percutaneous biopsy. Following on-site cytopathological diagnosis of
cancer, one additional fine needle aspiration was performed to obtain cells.
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Protein expression
Protein expression was measured by western blot. Myotubes were washed with phosphate
buffered saline, lysed (50 mM Tris, 150 mM NaCl, 10% (v/v) glycerol, 0.5% IGEPAL
CA-630,1 mM EDTA, containing Protease Inhibitor Cocktail (1:100, cat# P8340, Sigma)
and Phosphatase Inhibitor Cocktail 3 (1:100, cat# P0044, Sigma), incubated on ice for 30
min and then centrifuged at 14,000 × g at 4 °C for 10 min. Lysate protein contents were
measured (BioRad DC Protein Assay, Hercules, CA) and diluted in sample prep buffer
(62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 1% SDS 0.005% bromophenol blue, 5% 2mercaptoethanol). Proteins were separated by SDS-PAGE (Bio-Rad, Hercules, CA,
USA), transferred to polyvinylidene (PVDF) membranes and blocked with TBST buffer
(150 mM NaCl, 0.05 % Tween-20, and 20 mM Tris-HCl, pH 7.4) containing 5% nonfatty milk or BSA. After blocking, membranes were incubated overnight with myosin
primary antibody (1:20000, Sigma M4276, RRID: AB_477190). Membranes were
washed for 30 min in TBST and then incubated for 1 h at room temperature in 5% milkTBST containing Anti-Mouse IgG-Peroxidase (1:15000, Sigma A2304, RRID:
AB_257993) secondary antibody with Clarity Western ECL Substrate (Bio-Rad,
Hercules, CA, USA).

Myotube mitochondrial content and reactive oxygen species (ROS) production
Mitochondrial content and ROS production were measured with fluorometric dyes, as
described (25). Briefly, C2C12 myotubes grown in 35 mm dishes or black-walled 96 well
plates were loaded with fluorescent dyes to assess mitochondrial content (1 μM
MitoTracker Green FM; 490/516 nm) and ROS production (1 μM MitoSOX Red;
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510/580 nm; both Molecular Probes, Eugene, OR) 15 minutes prior to measurement.
Fluorescence was measured on a microplate reader (BioTek, Winooski, VT) and the
MitoSox signal was expressed relative to MitoTracker signal to control ROS production
for mitochondrial content.

Statistics
Analysis of variance (ANOVA) was used to compare treatments. Most studies examining
CM treatment have compared CM application to a single control condition. Thus, we also
made pairwise comparisons between CM and all three control conditions using unpaired
t-test.
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Results
Characteristics of C2C12 myotube cultures. C2C12 myotubes were differentiated for 7
days before treatment with CM. Under our culture conditions, there is rapid growth and
accumulation of myosin between d3 and d7, followed by a relative plateauing of myotube
myosin content and diameter (data not shown). At d7, myotubes express myofilament
proteins, including myosin, actin, and α-actinin, and organize these proteins into
myofilaments (data not shown). Myofilaments and components of the excitationcontraction coupling system are functional at this time, as electrical field stimulation
causes intracellular Ca2+ cycling and contraction, which can be prevented by
pharmacological inhibition of excitation contraction coupling with the sodium channel
blocker tetrodotoxin (data not shown). Thus, at this stage of differentiation, myotubes
exhibit numerous hallmark characteristics of in vivo muscle.
LLC and Kras CM. We began by testing the effects of LLC CM, as this cell line is
widely used to promote cachexia in mouse xenoplant models (4, 8, 11). In C2C12
myotubes differentiated for 7 days, we found no differences in myosin content among
LLC CM, HBSS dilution control and NL20 control CM and untreated controls (Figure
1A) when analyzed via ANOVA. Moreover, because many studies only compare LLC
CM to a single control, we also performed pairwise comparisons between LLC CM and
different control conditions (untreated control, HBSS dilution control or NL20 control)
by unpaired t-tests. There were still no effects of LLC CM on myotube myosin content
with this different analytical approach. We found an effect of KrasG12D CM on myotube
myosin content (Figure 1B), but it paradoxically increased myosin content compared to
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all control conditions (P=0.002) using either ANOVA or pairwise analytical approaches
(P<0.01).
Timing of CM application. Reasons for the absence of effects of CM are uncertain, but
one difference between our protocol and the majority of studies in the field is that we
used myotubes that were differentiated for 7 days prior to CM application. Most studies
have treated myotubes at day 4 or 5 post-differentiation. Thus, we also examined the
effects of CM on myotubes starting at day 4 post-differentiation. Under these conditions,
we observed a 32% reduction in myosin content (P<0.05 using either ANOVA or
pairwise analytical approaches) in response to LLC CM compared to untreated control
(Figure 2A). However, a similar reduction in myosin content was noted with CM from
the non-tumorigenic NL20 cell line (33%, P<0.05 using either ANOVA or pairwise
analysis) and a trend for lower myosin content was observed in the HBSS dilution control
(P=0.07 pairwise analysis, P=0.08 ANOVA) compared to untreated controls (Figure 2A).
Similarly, using Kras CM administered at day 4 post-differentiation, we found a 36%
reduction in myosin content with KrasG12D CM (P<0.05 ANOVA or pairwise analysis).
However, we also observed a reduction 38% in myosin content with CM from KrasWT
cells (P<0.05 ANOVA or pairwise analysis) and 39% reduction with the HBSS dilution
control (P<0.05 ANOVA or pairwise analysis) when compared to untreated controls
(Figure 2B).
Mitochondrial content and ROS production with murine CM. Recent reports have
suggested a role for oxidant stress in the atrophic effect of tumor-related factors (3, 16,
20, 31, 60). Thus, we examined the effects of CM on mitochondrial content and ROS
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production. LLC treatment of myotubes 7 days post-differentiation did not alter
mitochondrial ROS production (Figure 3A), nor did treatment with any of the control
conditions, whether we utilized ANOVA or pairwise comparisons. Mitochondrial content
was also unchanged with HBSS, NL20 or LLC treatment (Figure 3B). With Kras
experiments on day 7 post-differentiation myotubes, there was no change in ROS
production compared to untreated controls (Figure 3C), but both KrasG12D (P<0.01
ANOVA or pairwise analysis) and KrasWT (P<0.01 ANOVA or pairwise analysis) CM
increased mitochondrial content (P<0.01; Figure 3D) when measured with ANOVA or
pairwise comparisons.
When LLC CM was applied to d4 myotubes, no changes in ROS were found
(Figure 4A). However, mitochondrial content was elevated with NL20 CM (P<0.01
ANOVA or pairwise analysis) (Figure 4B). Kras CM increased ROS production in d4
myotubes with both KrasG12D (P<0.01) and KrasWT (P<0.01) CM (Figure 4C), but not
with HBSS control dilution. Mitochondrial content was also increased by KrasG12D
(P<0.01) and KrasWT (P<0.01) CM (Figure 4D) relative to untreated controls when
measured with either ANOVA or pairwise analysis.
Myotube myosin content with human CM. Informed by the results of LLC and Kras
studies, we decided to test CM from patient lung cancer biopsies on d7 myotubes, as we
reasoned that effects of CM observed on d4 myotubes were due to growth inhibition,
rather than a unique effect of tumor-derived factors on myotubes. We treated d7
myotubes with patient tumor CM from 4 patients (human tumor conditioned media;
hTCM), non-cancer control cells (human bronchial epithelial cells; HBEC), HBSS
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dilution controls, and untreated controls for 3 days with serum content constant among all
groups. We found no effect of patient lung tumor primary cell CM on myosin content
compared to untreated and saw no reduction with any of the treatment groups (Figure
5A). Similarly, we found no effect of patient lung tumor primary cell CM, non-cancer
control cell CM or dilution control compared to untreated control (Figure 5B). We
observed an effect of hTCM (+19%, P<0.01) and HBEC CM (+16%, P<0.05) to increase
mitochondrial content compared to untreated controls, but no effect of HBSS dilution
control (Figure 5C) when measured with either ANOVA or pairwise analysis.
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Discussion
Conventional wisdom holds that tumors release soluble factors that act on distal
skeletal muscle tissue to cause atrophy and other metabolic derangements in cancer
patients. We evaluated this proposition by testing the effects of murine and human lung
tumor cell CM on C2C12 myotube cultures, a common model to test for tumor cellderived atrophic factors (11, 35, 36, 38, 44, 51, 68). Our studies included controls to
account for dilution of media, factors released into media by growing cells and the timing
of CM application relative to the start of differentiation. When we examined the effects
of murine lung tumor cell CM 7 days post-differentiation, when myotubes express
structural and functional phenotypes common to in vivo skeletal muscle, we found no
atrophic effects of murine tumor CM on myotubes. Although murine lung tumor cell CM
reduced myosin content and caused mitochondrial adaptations when applied to myotubes
differentiated for 4 days compared to untreated controls, similar effects were observed
with control cell CM and HBSS dilution controls. Finally, to our knowledge, we present
the first report of the effect of CM from primary cultures of human lung tumor cells on
cultured myotubes. Similar to murine cancer cell CM, however, we found no evidence for
an effect of human tumor CM on myotubes. Our results argue against the hypothesis that
factors released from tumor cells contribute to skeletal muscle atrophy and mitochondrial
abnormalities.
Cultured muscle cells are a unique and valuable system that permits examination
of muscle in isolation, with the ability to manipulate the extracellular environment.
Despite these strengths, studies in cultured muscle cells are criticized because of the
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artificial nature of this system. While a myotube is not a perfect model of a muscle fiber,
how well this system models in vivo muscle may vary depending on its stage of
differentiation. Treatment of myotubes with either murine or human tumor cell CM
starting at 7 days post-differentiation had no effect on either myotube myosin content or
mitochondrial content/ROS production compared to untreated controls. In fact, in the
case of KRASG12D cells, CM paradoxically enhanced myotube myosin and mitochondrial
content compared to untreated controls. In contrast to results on 7 day differentiated
myotubes, CM had effects on cells treated at 4 days post-differentiation, causing myosin
depletion and some mitochondrial adaptations. The failure to observe effects at 7 days
post-differentiation is unlikely related to the cell lines used, as LLC is well-proven to
cause cachexia when transplanted into mice (12, 34, 45, 65) and when LLC CM has been
applied to cultured myotubes (21, 36, 38, 39, 67). KRASG12D is less well-described, but
data from our labs (unpublished data) and others show that KRASG12D mice experience
muscle atrophy (40). One could argue that myotubes at this later developmental stage are
recalcitrant to atrophic stimuli. However, the application of various chemotherapeutics
provokes atrophy at this time (24), in agreement with studies by other laboratories on
myotubes studied earlier following differentiation (22).
Our data from experiments treating 4-day differentiated myotubes with LLC and
KRASG12D CM argue that a dilution effect caused by the addition of the CM to standard
DM impairs myotube growth. Numerous studies have shown that C2C12s are still
increasing in size and myosin content from day 4 to day 7 post-differentiation (13, 14, 26,
41, 54, 57, 61). Media dilution with CM may simply starve cells of nutrients required for
normal growth. A recent study by Jackman et al. supports this interpretation (27). In this
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study, 4 -day post-differentiation myotubes were treated for 3 days with tumor cell CM
and compared to untreated DM, similar to the current study. Time course data show that
the effect of CM was not to induce atrophy but to impair the growth of myotubes. Our
HBSS dilution control further supports the effects of the CM dilution on myotube growth.
Thus, we conclude that compared to control cells maintained in undiluted DM, the effects
of tumor cell CM on 4 day differentiated myotubes primarily reflects growth inhibition.
If media dilution impairs myotube growth, a more valid control would be a cell
type similar to the tumor cell line, but that does not release factors that cause muscle
wasting. Because the identity of these secreted factors is unknown, the selection of
appropriate control cell lines is difficult. We used CM from a similar lung epithelial cell
type compared to tumor cell lines. In the control for LLC CM, we used the nontumorigenic NL20 cells (21, 49, 50, 71), which is used widely in the field as a control for
LLC CM (66, 68, 69). This is not an ideal cell line because of species differences, but it is
non-tumorigenic in animals and grows well under similar media conditions as LLC cells
and has been used as a control for LLC CM in past studies (46, 70).
Concern about the appropriateness of the control cell line is lessened in the Kras
CM experiments, where we used a Cre recombinant adenovirus to activate the oncogenic
KRAS mutation (KrasG12D) or treatment of cells with an empty vector as a control
(KrasWT). Thus, with the exception of Cre expression and transgene activation, the
KrasWT cells are identical to KrasG12D cells. CM from KrasWT controls, therefore, should
reflect the effects of nutrient depletion, secreted factors and/or metabolic by-products
typical to growing cells, only differing from KrasG12D CM for those secreted factors that
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contribute to cachexia. As with LLC CM experiments, data from these controls largely
mirrored that of HBSS dilution controls and KrasG12D CM, further supporting the
conclusion that most of the effects of tumor cell CM observed in prior work is related to a
dilution effect when comparisons are made to cells maintained in untreated (i.e.,
undiluted) control media. Thus, our data collectively argue against the hypothesis that
factors secreted from tumor cells act directly on skeletal muscle cells to provoke atrophy
and mitochondrial maladaptations.
Several caveats to our studies deserve discussion. First, we are examining the
direct effects of CM on skeletal muscle. Muscles contain an array of other cell types
(immune cells, satellite cells, fibroblasts, etc.) that could respond to tumor-derived factors
to provoke atrophy. For instance, tumor CM may mediate its effects through host
inflammatory response to tumor presence, either systemically or locally within the
muscle (5, 9). Our experiments did not test potential host-specific host-derived factors.
Second, we used the common 1:3 dilution of DM with CM to treat the cultured
myotubes. The amount of secreted factors in this dilution, and the fact that we exposed
myotubes to a single bolus of the CM (media changed daily), may be insufficient to
promote skeletal muscle myotube atrophy. To the first point, considering the relatively
small size of most human tumors relative to the systemic circulation and interstitial fluid
volumes, such a dilution would seem far in excess of what skeletal muscles are exposed
to in vivo. To the latter point, recent studies have argued that co-culture of tumor cells
and muscle myotubes is required to observe a true atrophic effect of tumor-secreted
factors to cause atrophy (27). While this may be the case, as we have demonstrated with
our various control conditions, appropriate control cell lines are needed to assure that
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myotube atrophy is not provoked by media substrate depletion and/or accumulation of
metabolic waste products. Finally, our model is uncoupled from the complex clinical
condition present in cancer patients, such as pulmonary insufficiency, chemotherapeutics
and muscle disuse. The effects of these clinical factors may cause skeletal muscle to be
more responsive to tumor-related factors that incite muscle wasting.
In summary, we found no evidence that tumor-secreted factors influence skeletal
muscle. Although the common experimental model of using 4 day differentiated
myotubes for treatment yielded lower myotube myosin content compared to untreated
controls, these decreases were not apparent when compared to controls for media dilution
or other secreted factors, suggesting that CM effects are most likely related to media
dilution and growth inhibition, rather than atrophy. Finally, to our knowledge, this is the
first report of the effects of human tumor primary cell CM on cultured myotubes. Similar
to results from murine tumor cell CM, we found no effect of human tumor cell CM on
myotube myosin content or mitochondrial content or ROS production. Collectively, our
results argue against direct effects of tumor secreted factors on skeletal muscle to cause
atrophy and metabolic dysfunction.
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Figures & Tables

Figure 2.0.1: The effects of murine CM on d7 myotubes.
Figure 1. Effects of 3 d of murine LLC (A; gray bar) or KrasG12D (B; gray bar)
conditioned media (CM; 1:3) treatment on myosin content in d7 differentiated myotubes
compared to undiluted (CTRL; open bars), dilution (HBSS; 1:3; hatched bar) and nontumorigenic (NL20 and KrasWT cells; 1:3; hatched bars) controls. (A) No effect of LLC
CM was found compared to CTRL or non-tumorigenic NL20 or HBSS controls (n=6/bar).
(B) KrasG12D CM increased myotube myosin content compared to CTRL and both
KrasWT and dilution controls (n=6/bar). Representative gel images are shown at the top
of panels A and B for a subset of replicates. All data are mean ± SEM, with individual data
points shown with each bar. **, P<0.01.
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Figure 2.0.2: The effects of murine CM on d4 myotube myosin.
Figure 2. Effects of 3 d of murine LLC (A; gray bar) or KrasG12D (B; gray bar)
conditioned media (CM; 1:3) treatment on myosin content in d4 differentiated myotubes
compared to undiluted (CTRL; open bars), dilution (HBSS; 1:3; hatched bar) and nontumorigenic (NL20 and KrasWT cells; 1:3; hatched bars) controls. (A) LLC and NL20 CM
reduced and HBSS tended to reduce myotube myosin content compared to CTRL. (B)
KrasG12D and KrasWT CM and HBSS reduced myotube myosin content compared to
CTRL. Representative gel images are shown at the top of panels A and B for a subset of
replicates. All data are mean ± SEM, with individual data points shown with each bar.*,
P<0.05; †, P<0.10.
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Figure 2.0.3 The effects of murine CM on d7 myotube mitochondria
Figure 3. Effects of 3 d of murine LLC (A and B; gray bar) or KrasG12D (C and D; gray
bar) conditioned media (CM; 1:3) treatment on mitochondrial reactive oxygen species
(ROS) production and mitochondrial content in d7 differentiated myotubes compared to
undiluted (CTRL; open bars), dilution (HBSS; 1:3; hatched bar) and non-tumorigenic
(NL20 and KrasWT cells; 1:3; hatched bars) controls. No differences were found between
LLC or NL20 CM or HBSS dilution or untreated (CTRL) controls for mitochondrial ROS
(A) or content (B) (n=12/bar). (C) No differences were found between KrasG12D and
KrasWT CM or HBSS dilution or untreated (CTRL) controls for mitochondrial ROS
(C)(n=12/bar). (D) Both KrasG12D and KrasWT CM increased mitochondrial content
compared to HBSS and CTL conditions (n=12/bar). All data are mean ± SEM, with
individual data points shown with each bar.**, P<0.01.
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Figure 2.0.4: The effects of murine CM on d4 myotube mitochondria.
Figure 4. Effects of 3 d of murine LLC (A and B; gray bar) or KrasG12D (C and D; gray
bar) conditioned media (CM; 1:3) treatment on mitochondrial reactive oxygen species
(ROS) production and mitochondrial content in d4 differentiated myotubes compared to
undiluted (CTRL; open bars), dilution (HBSS; 1:3; hatched bar) and non-tumorigenic
(NL20 and KrasWT cells; 1:3; hatched bars) controls. No differences were found between
LLC or NL20 CM or HBSS dilution or untreated (CTRL) controls for mitochondrial ROS
(A)(n=12/bar). (B) NL20 CM increased mitochondrial content compared to LLC, HBSS
or CTRL conditions (n=12/bar). Both KrasG12D and KrasWT CM increased
mitochondrial ROS production (C) and content (D) compared to either HBSS dilution or
untreated (CTRL) controls (n=12/bar). All data are mean ± SEM, with individual data
points shown with each bar. **, P<0.01.
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Figure 2.0.5: The effects of human CM on d7
myotubes.
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Figure 5. Effects of 3 d of treatment with primary human tumor cell conditions media
(hTCM; 1:3; gray bars) on myosin protein content (A) and mitochondrial reactive oxygen
species (ROS) production (B) and content (C) in d7 differentiated myotubes compared to
undiluted (CTRL), dilution (HBSS; hatched bars) and primary human bronchial epithelial
cell (HBEC; 1:3 dilution; hatched bars) controls. No differences were found between
treatments for myotube myosin content (A) or mitochondrial ROS production (B) (n=1224/bar). (C) Both hTCM and HBEC increased mitochondrial content compared to HBSS
dilution and untreated (CTRL) controls (n=12-24/bar). All data are mean ± SEM, with
individual data points shown with each bar.*, P<0.05.
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Table 2.1: Physical and disease characteristics in cancer patients

n
Age (yr)
Sex (M/F)
BMI
Weight loss Reported
Cancer Stage (I/II/III/IV)
Diagnosis (n)
NSCLC
SCLC
Histology (n)
Adenocarcinoma
Basaloid Squamous Cell
Neuroendocrine

4
76 ± 7
1,3
23.5 ±
4
0
0,1,1,1
3
1
2
1
1

Chemotherapeutics (n)
Paclitaxel
Carboplatin
Pembrolizumab
Pemetrexed
Radiation (n)

1
2
1
1
1
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Abstract
How breast cancer and its treatments affect skeletal muscle is not well defined. To
address this question, we assessed skeletal muscle structure and protein expression in 13
women diagnosed with breast cancer, who were receiving adjuvant chemotherapy
following tumor resection, and 12 non-diseased controls. Breast cancer patients showed
reduced single muscle fiber cross-sectional area (CSA) and fractional content of both
sub-sarcolemmal and intermyofibrillar mitochondria. Drugs commonly used in breast
cancer patients (doxorubicin and paclitaxel) caused reductions in myosin expression,
mitochondrial loss and increased reactive oxygen species (ROS) production in C2C12
murine myotube cell cultures, supporting a role for chemotherapeutics in the atrophic and
mitochondrial phenotypes. Additionally, concurrent treatment of myotubes with
mitochondrial-targeted antioxidant (MitoQ) prevented chemotherapy-induced myosin
depletion, mitochondrial loss, and ROS production. In patients, reduced mitochondrial
content and size, and increased expression and oxidation of peroxiredoxin 3, a
mitochondrial peroxidase, were associated with reduced muscle fiber CSA. Our results
suggest that chemotherapeutics may adversely affect skeletal muscle in patients and that
these effects may be driven through effects of these drugs on mitochondrial content
and/or ROS production.

Keywords: cachexia, mitochondria, myotube
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Introduction
Cancer and its treatment can affect skeletal muscle. The most widely studied
consequence is cachexia, a syndrome characterized by fat and skeletal muscle tissue
depletion that typically occurs in late-stage disease (17). Most studies have evaluated
skeletal muscle from patients with cancers that are prone to cachexia and model systems
that mimic them. However, patients with other cancer types less prone to cachexia, or
those with early-stage disease, may also experience muscle atrophy (21) and dysfunction.
Despite the fact that these patients comprise the majority of cancer survivors, our
understanding of the effect of these cancer types and their treatments on skeletal muscle
is limited.

Breast cancer, the most commonly diagnosed cancer in the US (1), is thought to have
minimal effects on skeletal muscle because patients are less prone to cachexia (16) and
are typically weight-stable or gain weight during treatment (30). This constancy in body
weight, however, belies reciprocal changes in body composition, specifically a gain in fat
and a loss of lean tissue (21). Muscle atrophy and the resulting weakness have prognostic
importance in breast cancer patients (6, 9, 60), underscoring the need to better understand
the effects of this cancer type and its clinical sequelae on skeletal muscle.

In the present study, our objective was to examine skeletal muscle in patients receiving
adjuvant chemotherapy following tumor resection and in healthy controls without a
history of cancer. We hypothesized that cancer therapeutics might promote skeletal
muscle adaptations in patients, as drugs commonly used in breast cancer, such as
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anthracyclines, cause muscle wasting and dysfunction in pre-clinical models (22, 25, 43),
whereas breast cancer tumors do not (27, 61). More specifically, we hypothesize that
chemotherapeutics have myotoxic effects through their ability to provoke mitochondrial
dysfunction and oxidative stress, as studies suggest that mitochondrial remodeling and
oxidant stress promote skeletal muscle atrophy (48, 51). To begin to address this
possibility, and building on pre-clinical studies showing that chemotherapeutics have
effects on mitochondrial biology (3, 43), we also assessed mitochondrial
content/morphology and markers of oxidative stress. Finally, we employed the C2C12
murine muscle cell line, as we could not ascribe muscle morphological and mitochondrial
phenotypes in humans to chemotherapeutics because of the complex clinical background
of these patients and our case-control study design. Cultured muscle cells provide a
model where the singular effect of chemotherapeutics can be evaluated independent of
clinical factors associated with treatment in patients, as well as effects on other tissue and
organ systems. This latter point is particularly relevant to anthracyclines, which cause
cardiac damage and heart failure in animal models (26), a syndrome that could affect
skeletal muscle (54). Though there are the limitations of C2C12 myotube cultures, results
from these experiments can be used as proof-of-principle evidence that
chemotherapeutics may have effects on skeletal muscle to provoke phenotypes observed
in human patients.
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Methods
Subjects. Thirteen women with breast cancer were recruited. Patients were included if
they had stage I, II or III, histologically documented breast cancer and were receiving or
scheduled to receive chemotherapy following surgical resection. We excluded patients
with prior history of cancer, other than non-melanoma skin cancer, prior
chemotherapeutic use, autoimmune, vascular or neuromuscular disease or prior knee or
hip replacement surgery. All patients received dexamethasone for 1 to 4 days concurrent
with chemotherapy administration to prevent adverse drug reaction and diminish cancerinduced nausea and vomiting. Patients could receive a maximum dose of 12 mg on the
day of chemotherapy and 4 mg per day for 3 days thereafter as symptoms necessitate. As
dosing was symptom-dependent and not tracked clinically, exact doses for
dexamethasone treatment are not available. Three patients were characterized as having
experienced weight loss, defined as self-reported, unintentional weight loss >5% of body
weight within 6 months prior to evaluation; whereas, other patients who reported little or
no weight change (<5%) were characterized as weight stable. All patients were tested
during adjuvant chemotherapy, prior to radiation therapy. One patient reported current
tobacco use (44 pack year history). None of the patients received nutritional support or
anabolic therapy or were taking medications known to influence skeletal muscle size or
function aside from chemotherapeutics. One volunteer was on a stable regimen of HMG
CoA reductase inhibitor, which our recent work suggests would not affect the variables
assessed in this study (50).
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Healthy female controls (n=12) were recruited if they were free from acute or chronic
disease, based on medical screening and routine clinical/laboratory tests, and had no prior
history of cancer, chronic lung or cardiovascular disease, neurological or orthopedic
conditions, or other mobility-limiting ailments. Volunteers were excluded if they were a
current or previous smoker or were taking medications that could influence skeletal
muscle, with the exception of stable HMG CoA reductase inhibitor treatment (n=1).
Plasma creatine kinase levels were within the normative range in this volunteer and she
reported no muscle symptoms. Written informed consent was obtained from all
volunteers prior to their participation and protocols and procedures were approved by the
Committees on Human Research at the University of Vermont.

Total and regional body composition. Body weight was measured on a digital scale
(ScaleTronix, Wheaton, IL). Total and regional body composition was measured by dual
energy x-ray absorptiometry, as described (57).

Muscle tissue processing. Percutaneous biopsy of the vastus lateralis was performed at
the mid-way point between the most proximal aspect of the patella and the inguinal fold.
The skin was sterilized (2% chlorhexidine/70% isopropyl alcohol) and local anesthetic
(1% lidocaine) infiltrated into the site, as described (55). A small incision (~5 mm) was
made through the skin, fat and fascia and the biopsy needle (5 mm Bergstrom) advanced
past the fascia into the muscle at an angle approximately 30-45° to the skin surface to
position the needle roughly parallel with the muscle fascicles, as described (15), to collect
long, intact bundles of fibers. Suction was applied and tissue was excised. Tissue for
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electron microscopy (EM) was tied to a glass rod at a slightly stretched length and placed
into glutaraldehyde/paraformaldehyde (2.5%/1%) for electron microscopy (EM). Tissue
for immunohistochemistry was embedded in optimal cutting temperature medium and
frozen in isopentane cooled in liquid nitrogen. Tissue was also taken for measurement of
mechanical properties of skeletal muscle fibers, but those data are not presented.
Remaining tissue was frozen in liquid nitrogen and stored at -80°C until analysis. In one
breast cancer patient, sufficient tissue was obtained only for EM analysis.

Immunohistochemistry. Muscle fiber cross-sectional area (CSA) and myonuclear
number were quantified by immunohistochemistry using rabbit anti-laminin (Abcam) and
mouse anti-MHC I antibodies (DSHB), as described (11). Nuclei were stained with 4',6diamidino-2-phenylindole (Invitrogen). CSA measurements were performed using image
analysis software (NIH ImageJ, version 1.51n). Although the myonuclei count will
include muscle satellite cells, these are a small fraction of the nuclei under the laminin
border (<5%; (46)). For healthy controls, immunohistochemistry was available on 5
volunteers because of limited tissue.

Myosin heavy chain (MHC) content and isoform distribution. MHC content and
isoform distribution were measured in tissue homogenates via gel electrophoresis, as
described (58), as a marker of the relative fiber type distribution of muscle.

Electron microscopy. EM was conducted on intact (i.e., unskinned) skeletal muscle
fibers to assess intermyofibrillar and sub-sarcolemmal mitochondrial area fraction,
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average area and number, as estimates of mitochondrial content, and myofibrillar
fractional area, as described (10).

Cell culture. Cultured murine myotubes were used to evaluate the singular effect of
chemotherapy agents on skeletal muscle cell biology; primarily, mitochondrial content
and oxidant production. Use of this system obviates the possible secondary effects of
these drugs on muscle through effects on other organs/tissue systems (e.g., cardiac
damage and failure due to doxorubicin administration (26)), which could affect skeletal
muscle (54)). The C2C12 model has been used to characterize the effects of tumorderived factors on mitochondrial oxidant production (39), effects that have been
confirmed in vivo in pre-clinical models (7).

C2C12 myoblasts (ATCC® CRL-1772™, Manassas, VA) were cultured in low glucose
(1 g/L), Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS; Gibco™ Thermo Fisher Scientific Waltham, MA) and antibiotics
(50 U/ml penicillin and 50 μg/ml streptomycin). Cells were plated (1.5 X 104 cells/cm2)
on Matrigel (40 μg/cm2; Corning, Bedford, MA) and switched to low serum, high glucose
(4.5 g/L) DMEM (1% heat-inactivated FBS) to induce differentiation, as generally
described (34). On day 7 post-differentiation, myotubes were treated with doxorubicin
(DOX), paclitaxel (TAXOL) (both Sigma, St. Louis, MO), cisplatin (CIS; Tocris,
Minneapolis, MN) or respective vehicle control (DMSO for DOX and TAXOL and PBS
for CIS) for 3 days. DOX dose was based on prior work (24) and serum concentrations
(47). TAXOL (66) and CIS (56) doses were based on tumor intracellular levels. In all
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cases, preliminary dose response studies were undertaken to obtain doses for DOX (0.2
μM), TAXOL (40 nM) and CIS (10 µM) that elicited loss of myotube myosin content
over the 3 day study period. In DOX and TAXOL experiments, where increased oxidant
generation was noted (Figure 5 and 6), MitoQ (MedKoo Biosciences, Morrisville, NC), a
mitochondrial-targeted anti-oxidant was added concurrent with chemotherapeutics to
determine whether decreasing mitochondrial oxidant stress prevents atrophy. MitoQ has a
narrow therapeutic range, a characteristic that we found varied by chemotherapeutic.
Accordingly, doses were 0.25 μM for DOX and 0.125 μM for TAXOL. On the final day
of treatment, myotubes were harvested for protein expression via western blot or
underwent mitochondrial measurements.

No genetic testing was conducted to validate the cell line. However, upon serum
withdrawal, these cells fuse to form multinucleated cells (Figure 5) and express
myofilament proteins, such as myosin, actin, and α-actinin (unpublished data). At day 7
post-differentiation, when chemotherapy treatment began, myotubes contain
myofilaments, contract with electrical stimulation and demonstrate intracellular calcium
release and reuptake (unpublished data). All of these anatomic and physiologic
characteristics have been demonstrated in C2C12 myotubes previously (33, 34, 38).
Additionally, we found that electrically stimulated contraction could be mitigated by
blocking either sodium channels with tetrodotoxin or myosin ATPase activity with Nbenzyl-p-toluene sulphonamide, with the former mitigating intracellular calcium currents
and contractures and the latter only mitigating contractures (unpublished data). Here
again, these characteristics of the contractile response and its sensitivity to specific
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pharmacological agents have been demonstrated by others (14, 44). Thus, C2C12
myotubes demonstrate many classical phenotypes of in vivo skeletal muscle.

Myotube mitochondrial content and reactive oxygen species (ROS) production.
Mitochondrial content and ROS production were measured with fluorometric dyes, as
described (45, 64) with minor modifications. C2C12 myotubes grown in black-walled,
96-well plates were loaded with fluorescent dyes to assess mitochondrial content (1 μM
MitoTracker Green FM; 490/516 nm) and ROS production (1 μM MitoSOX Red;
510/580 nm; both Molecular Probes, Eugene, OR) 15 minutes prior to measurement.
Fluorescence was measured on a microplate reader (BioTek, Winooski, VT). The ROS
signal (MitoSox) was expressed relative to MitoTracker signal to control for any effect of
the chemotherapeutic to modify mitochondrial content. MitoTracker Green FM was
chosen because its labeling of mitochondria is insensitive to membrane potential, as this
could be affected by chemotherapeutics (23). To confirm co-localization of MitoTracker
and MitoSox signals in myotubes, myoblasts were plated (2.5 X 104 cells/cm2) on
Matrigel-coated (60 μg/cm2), 35 mm, glass bottom imaging dishes (MatTek; Ashland,
MA) and differentiated following procedures described above, with the exception that
media was changed daily for the first 3 days following the start of differentiation. Cells
were imaged on a Nikon Ti-E inverted microscope in a heated environmental chamber,
equipped with a Clara CCD camera (Andor) and Spectra X light engine.

Western blot analysis. Skeletal muscle tissue was homogenized, as described (59), in a
sub-set of patients (n=9) and controls (n=11), where tissue was available. In a sub-set of
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breast cancer patients (n=11), mitochondria were isolated, as described (35), and treated
as below for peroxiredoxin-3 (Prx 3) assessments. Myotubes were washed with
phosphate buffered saline, lysed (50 mM Tris, 150 mM NaCl, 10% (v/v) glycerol, 0.5%
IGEPAL CA-630,1 mM EDTA), incubated on ice for 30 min and centrifuged.
Homogenate, mitochondrial isolate, and lysate protein contents were measured (BioRad
DC Protein Assay, Hercules, CA) and diluted in gel loading buffer. For Prx 3, tissue
homogenates and myotube lysates were treated with N-ethylmaleimide (NEM) to prevent
oxidation and/or dimerization of Prx 3 during processing and then placed in gel loading
buffer with (reducing) or without DTT (non-reducing). Oxidation of Prx 3 can be used as
a marker of intracellular oxidative stress (49) and mitochondria specifically, as Prx 3 is
localized to mitochondria. The importance of Prx 3 in muscle is underscored by studies
showing that altered expression modulates mitochondrial content, morphology, and
function, as well as muscle contractility (36). Proteins separated by SDS-PAGE were,
transferred to nitrocellulose (Prx 3) or polyvinylidene (PVDF; all others), blocked (either
BSA, non-fat milk in Tris-buffered saline, or Odyssey Blocking buffer) and incubated
overnight with Prx 3 (1:6000; Cat# LF-PA0030, Thermo Fisher), p38 (1:1000; Cat#
9112, Cell Signaling), phospho-p38 (Thr 180/Thr 182; 1:500; Cat# 4511, Cell Signaling),
ERK1/2 (1:1000; Cat# 9102, Cell Signaling), phosoho-ERK1/2 (Thr 202/Thr 204; 1:500;
Cat# 9106, Cell Signaling), α-tubulin (Cat# 12G10, Developmental Studies Hybridoma
Bank; 0.5 μg/mL), detyrosinated α-tubulin (1:500; Cat# ab48389, Abcam), myosin fast
(1:15000; Cat# M4276, Sigma) antibodies or GAPDH (1:5000; Cat# MCA4739, Biorad).
Blots were washed and incubated with secondary antibodies conjugated to horseradish
peroxidase and developed by chemiluminescence (Clarity Western ECL Substrate
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BioRad, Hercules, CA) or the Odyssey Infrared Imaging System (for p38, ERK1/2 and
tubulin analytes; IRDye 680 or IRDye 800 secondary antibodies; both LiCor, Lincoln,
NE). Bands were quantified by densitometry (Quantity One; BioRad, Hercules, CA or
Odyssey Application Software v3.0; LiCor, Lincoln, NE). For analysis that required
running more than one gel, data were normalized to an internal loading control to permit
comparisons across gels. Technicians were blinded to group assignment or treatment.

Statistics. Differences between groups were determined using unpaired t-tests. For
variables with multiple observations within the same individual (e.g., single fiber CSA), a
linear mixed model was used, including a between-subject effect of group assignment
(control or cancer) and a repeated effect to account for variation in fiber characteristics
within each individual. This effect accounts for the fact that each fiber within an
individual is not independent and has some relationship to other fibers within that
individual. The mixed model is preferable to taking an average value for each individual,
which makes the erroneous assumption that within-subject variation is zero. Instead, the
mixed model considers this within-subject variation in the derivation of within-group
variance to test for fixed effects (i.e., group differences). Least squared mean and
variance estimates are used to test for fixed effects in the mixed model. However,
arithmetic means are displayed figuratively and in the text to correspond with individual
data (or individual average data for variables with multiple observations per volunteer),
the latter of which is plotted to illustrate the spread of data. For cell culture experiments,
unpaired t-tests or one-way analysis of variance were used. Finally, relationships between
variables were determined by Pearson correlation coefficients, with normality confirmed
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by Shapiro-Wilk test. For non-normally distributed variables that remained so following
data transformations (e.g., MHC II CSA), Spearman rank correlation coefficients were
used. SPSS (version 23, IBM Co., Armonk, NY) was used for all statistical analysis,
except mixed model analysis (SAS, version 9.4, SAS Institute Inc., Cary, NC). All data
are reported as mean ± SEM, unless otherwise specified.
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Results
Disease and physical characteristics. Controls were older, but groups were similar for all
body size and composition variables (Table 1). Disease and treatment characteristics of
patients are detailed in Table 1. Five patients reported unintentional weight loss during 6
months prior to testing (-4.0 ± 1.1 kg; range: 1 to 7 kg), with 3 (1 stage I, 1 stage II and 1
stage III) reporting >5% loss (-5.7 ± 0.7 kg). Breast cancer patients were studied an
average of 59 ± 10 d into their chemotherapy regimens (range: 5-114 d).

Single muscle fiber characteristics. Breast cancer patients showed lower single muscle
fiber CSA compared to controls (P<0.05; n=1682 and 450 fibers; Figure 1A), with lower
MHC II fiber CSA (P=0.05; n=745 and 228 fibers) and a trend toward lower MHC I CSA
(P=0.07; n=937 and 222 fibers). No differences in CSA were found between patients
reporting weight loss and those reporting weight stability in all fibers, or MHC I or II
fibers separately, (P>0.40; data not shown). Of note, as detailed in the Statistics section,
statistical tests for group differences are based on the number of volunteers per group, not
the total number of fibers. No differences were found in myonuclear number per fiber in
MHC I or II fibers (Figure 1B). Finally, we found no differences between groups for
myofibrillar fractional area by EM (Figure 1C) or myosin or actin protein in tissue
homogenates (Figure 1D).

Mitochondrial content and structure. In breast cancer patients, intermyofibrillar
mitochondria fractional area was lower (P<0.03) than controls (Figure 2A), due to
smaller (P<0.02) average mitochondrion area (Figure 2B), with no difference in number
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(control: 0.24 ± 0.03 vs. cancer: 0.29 ± 0.03 n/μm2). Similarly, sub-sarcolemmal
mitochondrial fractional area was reduced (P<0.05; Figure 2C) due to decreased number
of mitochondria per unit area (P<0.01; Figure 2D), while average sub-sarcolemmal
mitochondrion area showed a trend (P=0.07) towards being greater in cancer patients
(control: 0.95 ± 0.08 vs. cancer: 1.59 ± 0.26 µm2). Sub-sarcolemmal area did not differ
between groups (control: 21.7 ± 2.3 vs. cancer: 21.7 ± 1.6 µm2). Finally, in the breast
cancer patients, reduced intermyofibrillar mitochondrial size was associated with smaller
CSA in both MHC I (r=0.792; P<0.01) and II (r=0.769; P<0.01) fibers, whereas
intermyofibrillar mitochondrial size was not associated with CSA in either fiber type in
controls (both P>0.50). Reduced sub-sarcolemma mitochondrial fractional content was
associated with smaller MHC II CSA in cancer patients (r=0.743; P<0.01), but not
controls in either fiber type (P>0.60).

We examined whether differences in fiber type distribution, a marker of muscle fiber type
proportion, might account for variation in mitochondrial parameters. Breast cancer
patients were characterized by a lower fractional content of MHC I proteins compared to
controls (35.8 ± 0.8 vs. 39.0 ± 1.2%; P<0.05), although neither MHC IIA (36.3 ± 0.3 vs.
35.8 ± 1.0%) nor MHC IIX (27.9 ± 0.9 vs. 25.2 ± 1.5%) differed. Variation in MHC I
fractional content, however, was not associated with mitochondrial fractional content
from either compartment in the whole group or either group separately. Moreover, as
slopes of these relationships were shallow (range: -0.005 to 0.064), modest differences in
MHC I fiber fractional content would likely not explain group differences in
mitochondrial content in either compartment.
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Prx 3 expression. To examine whether mitochondrial oxidant stress in cancer patients is
associated with muscle fiber size, we evaluated the expression and oxidation state of the
mitochondrial-targeted anti-oxidant enzyme Prx 3 in a sub-group of breast cancer patients
(n=9). We found that expression of Prx 3 was negatively related to both MHC I and
MHC II CSA (Figure 3A and 3B, respectively). Moreover, in mitochondrial isolates
(n=11), increased amounts of oxidized Prx 3 in breast cancer patients was related to
decreased CSA in MHC II fibers (Figure 3C).

To further examine whether chemotherapeutics might contribute to variation in Prx 3
expression and/or oxidation, we treated C2C12 myotubes for 3 days with DOX or
TAXOL, two commonly used chemotherapeutics in our population (Table 1). DOX did
not affect Prx 3 expression, whereas TAXOL reduced Prx 3 expression (Figure 3D;
n=4/group). Note that the two bands shown under reducing conditions are due to the
addition of NEM to prevent oxidation and/or dimerization during processing, as samples
not treated with NEM showed only one band (data not shown). The above results reflect
quantification of both bands. Under non-reducing conditions, we found that DOX
increased oxidized Prx 3 in myotubes (P<0.05), as shown by increased Prx 3 dimer
(Control: 100 ± 8.9 vs. DOX: 162.5 ± 11.0 vs. TAXOL: 106.7 ± 6.1%; Figure 3E).
Because TAXOL reduced Prx 3 expression (Figure 3D), we calculated the relative
amount of dimer in each treatment group as a function of monomer + dimer as a marker
of mitochondrial oxidative stress. This did not alter the results, as oxidized Prx 3 in DOX
treated myotubes remained elevated (Figure 3F; n=4/group).
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Tubulin expression and detyrosination. Because mitochondrial motility and
communication occur via kinesin-dependent movement along microtubules, and because
taxane chemotherapeutics, which were taken by all breast cancer volunteers, alter tubulin
expression and post-translational modification in skeletal muscle, we examined the
effects of taxanes on tubulin expression and post-translational modification. In C2C12
myotubes, treatment with TAXOL (40 nM for 3 days; n=6) increased expression of
tubulin and detyrosinated tubulin (Figure 4A). Similarly, in patients treated with
therapeutic doses of taxane chemotherapeutics (n=9), we found increased tubulin and
detyrosinated tubulin expression compared to controls (n=11; Figure 4B, respectively).
Because TAXOL can increase ROS production in skeletal muscles, we examined whether
variation in tubulin or detyrosinated tubulin correlated with mitochondrial content or
morphology. The average area of intermyofibrillar mitochondria was inversely correlated
to α-tubulin (r=-0.472; P<0.05) and detyrosinated tubulin (r=-0.580; P<0.01). In subsarcolemmal mitochondria, α-tubulin was negatively correlated to fractional content (r=0.558; P<0.05) and number per area (r=-0.654; P>0.01) and positively related to average
area (r=0.582; P<0.01).

Chemotherapy-induced atrophy and oxidant stress. To further examine the effects of
chemotherapeutics on skeletal muscle cell size and mitochondrial content and ROS
production, C2C12 myotubes were treated with DOX, a chemotherapeutic with wellcharacterized myotoxicity, or TAXOL, the most common chemotherapeutic in our
cohort. Treatment with DOX or TAXOL reduced myosin content (Figure 5A; n=15 and
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9, respectively). That myosin content serves as a proxy of myotube cell size was
confirmed by the fact that DOX-induced changes in myotube diameter (-22 ± 7% relative
to controls; n=3 wells/condition) tracked closely with changes in myosin content (-21 ±
2%; n=10). Accordingly, we utilized myosin protein content as our index of myotube size
throughout our studies.

Both DOX and TAXOL caused a loss of mitochondrial content (-8 ± 2%, n=16, P<0.01
and -38 ± 3, n=12, P<0.001, respectively). Accordingly, ROS production, as reflected by
MitoSox signal, was expressed per unit MitoTracker signal to control for changes in
mitochondrial content. The use of MitoTracker signal to correct MitoSox signal is based
on the mitochondrial targeting of both probes, which we confirmed in our preparations
(Figure 6A). Both chemotherapeutics increased ROS production per unit MitoTracker
signal (Figure 5B; n=12 and 11, respectively). To examine whether increased ROS
production with chemotherapeutics contributes to myotube atrophy, we concurrently
treated cells with the mitochondrial-targeted anti-oxidant MitoQ and observed that it
prevented DOX- and TAXOL-induced loss of myosin protein content (Figure 5C and D;
n=12 and 3, respectively). Additionally, MitoQ application to myotubes prevented the
loss of mitochondrial content (Figure 6B and C; n=12 and 12, respectively) and prevented
(DOX) or lessened (TAXOL) the increase in ROS production (Figure 6D and E; n=12
and 12, respectively).

Our prior work showed mitochondrial rarefaction (-50%) in skeletal muscle from patients
with cancers that are prone to cachexia—primarily lung cancer—where platin-based
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drugs were the most common chemotherapeutic (58). To explore whether they have
effects similar to DOX and TAXOL, we evaluated the effects of CIS on C2C12
myotubes. CIS caused profound myosin loss (control: 100 ± 17% vs. CIS: 19 ± 4% of
control; n=3; P<0.01), but did not increase ROS production relative to MitoTracker
signal (control: 100 ± 1 vs. CIS: 98 ± 1% of control; n=12) and paradoxically increased
MitoTracker signal (control: 100 ± 6 vs. CIS: 113 ± 5 of control; n=12; P<0.01).

Signaling pathways. Recent studies suggested that upregulation of redox-responsive
signaling pathways, such as p38 and ERK1/2, may contribute to muscle atrophy with
chemotherapeutic administration in pre-clinical models. However, we found no
differences in the expression or phosphorylation of p38 (Figure 6A) or ERK1/2 (Figure
6B), nor the ratio of phosphorylated to total content of either, between patients (n=9) to
controls (n=11). ERK1/2 data represent quantitation of both bands.
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Discussion
Breast cancer patients showed evidence of muscle fiber atrophy and mitochondrial
rarefaction, with reduced muscle fiber size tracking, reduced mitochondrial content and
increased oxidant stress. Treatment with chemotherapeutics promoted these phenotypes
in cultured muscle cells, effects that were mitigated by concomitant treatment with a
mitochondrial-targeted antioxidant. These results provide seminal human data that
suggest deleterious effects of cancer treatments on muscle secondary to their mitotoxic
properties. That chemotherapeutics promote these adaptations provides a potential
explanation for muscle atrophy in cancers not prone to cachexia or early stage patients, as
well as the high prevalence of fatigue and physical disability across different cancer types
(12).

Reduced skeletal muscle fiber CSA in breast cancer patients was unlikely due to weight
loss, as few patients reported weight loss and fiber CSA did not differ between patients
reporting weight loss and those reporting weight stability. Other groups have reported
that lean tissue mass is reduced (21), but our report provides evidence of this using direct
measures of muscle cell size in breast cancer patients. We emphasize this point because
tissue level imaging-based measurements may not accurately reflect muscle size in
patients due to effects of treatments on tissue hydration (2). Indeed, we found no
differences between groups in leg muscle mass by DEXA (Table 1). Such discrepancies
in humans are not unique to this study, as we (42) and others (4) have shown discordance
between measures at these different anatomic levels under conditions when tissue
hydration may be altered (13). Although we acknowledge that biopsy samples represent a
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small amount of tissue relative to that sampled with imaging techniques, single fiber CSA
measurements agree well with imaging-based whole muscle CSA under stable
conditions, where muscle mass and hydration are not changing (11). This potential
limitation of imaging techniques is noteworthy because most studies to date have used
these approaches for defining cancer-related muscle atrophy in clinical populations.

This is the first report of skeletal muscle mitochondrial morphological adaptations in
breast cancer patients, a cohort with a low prevalence of cachexia, and is consistent with
our results in patients with cancers more prone to cachexia (58), albeit the reduction was
not as pronounced (current study vs. (58)). While cancer (62) or chemotherapeutics (3)
may reduce mitochondrial content, the fact that our patients had tumors removed
surgically and that breast cancer tumors generally do not promote cachexia in pre-clinical
models (27, 61) suggests chemotherapeutics as a more likely mediator. Indeed, recent
pre-clinical studies showed that administration of chemotherapeutics used for colorectal
tumors to mice reduced intermyofibrillar mitochondrial content secondary to decreased
mitochondrion size (3), a similar morphological phenotype as in our patients. Our results
also extend both pre-clinical and clinical work (58) to show mitochondrial loss in the subsarcolemmal compartment. Interestingly, different structural characteristics accounted for
reduced mitochondrial content in sub-sarcolemmal and intermyofibrillar compartments in
breast cancer patients, suggesting different mechanisms for mitochondrial remodeling in
the two compartments. Considering the beneficial effect of increasing or maintaining
mitochondrial content in other models of atrophy (52), therapeutics or interventions (e.g.,
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exercise) that preserve or increase mitochondria may prevent muscle atrophy and
weakness in cancer patients.

Chemotherapeutics may promote mitochondrial loss through their ability to provoke
mitochondrial dysfunction and oxidant production, as even modest amounts of oxidant
stress can promote mitophagy (20). To address this question, we utilized C2C12
myotubes to examine the singular effect of chemotherapeutics used in breast cancer
patients on mitochondrial content and oxidant production. We found that
chemotherapeutics caused mitochondrial loss and increased oxidant production in C2C12
myotubes. Moreover, treatment with the mitochondrial-targeted antioxidant MitoQ
prevented a loss of mitochondria, further implicating ROS in mitochondrial loss. In
contrast, mitochondrial content remained unchanged with CIS, another widely used
chemotherapeutic that did not increase ROS production. These data provide proof-ofprinciple evidence that mitochondrial loss tracks with drug-induced oxidant stress.

Another potential explanation for mitochondrial loss is the effect of taxane
chemotherapeutics on microtubules, as all of our patients were treated with these drugs.
Microtubules form a lattice in muscle fibers and serve as tracks to support kinesindependent mitochondrial movement (65) and communication (29). Pre-clinical studies
show that TAXOL increases the amount of tubulin and its detyrosinated form in skeletal
muscle (31), which we confirmed in C2C12 murine myotubes. Our results further provide
seminal data showing that taxanes at therapeutic doses used in human patients upregulate
tubulin and detyrosinated tubulin levels in skeletal muscle. That taxanes may have
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detrimental effects on mitochondria in patients is suggested by the negative correlations
of tubulin and detyrosinated tubulin to mitochondrial content and morphology in both
compartments. The mechanism whereby TAXOL affects mitochondria is not clear, but
our data in cultured myotubes and that of others in intact muscle fibers suggests that
TAXOL increases ROS production (Figure 4B and (32)), which could promote
mitophagy (20). In support of a role for ROS in promoting mitochondrial rarefaction, we
found that MitoQ prevented TAXOL-induced mitochondrial loss. Collectively, our
results highlight novel mitotoxic effects of taxane chemotherapeutics in skeletal muscle.

The effect of chemotherapeutics to increase cellular oxidant stress might also promote
myofiber atrophy (48). In patients, increased expression and oxidation of Prx 3, which
our data and that of others (37) from cultured muscle cells suggests may result from
chemotherapeutics, were associated with reduced CSA in MHC I and II fibers. Moreover,
in C2C12 myotubes, concomitant treatment with the mitochondrial-targeted anti-oxidant
MitoQ prevented chemotherapy-induced myosin loss. These findings are not confined to
cultured muscle cells, as mitochondrial-targeted antioxidants prevent DOX-induced
atrophy in rodents (43). Our data show that these effects are also apparent in cultured
muscle cells for TAXOL, the most commonly used drug among our breast cancer
patients. The mechanisms whereby increased cellular or mitochondrial oxidant stress
promotes muscle atrophy are not well defined and we found no evidence for activation of
p38 and ERK in breast cancer patients, signaling pathways that have been suggested to be
associated with the atrophic effects of chemotherapeutics in pre-clinical models (3). The
effects of chemotherapy may promote muscle atrophy through other signaling pathways
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that are sensitive to energetic/oxidative stress created by mitochondrial adaptations, such
as AMP-activated kinase (63), which can suppress protein synthesis and/or increase
proteolysis.

Not all chemotherapeutics derive their myotoxic effects through mitochondrial
adaptations, as we found marked myosin depletion in myotubes with CIS in the absence
of increased ROS production or mitochondrial rarefaction. The lack of an effect of CIS to
induce ROS production may be explained by the concentration we used, as prior work
suggests that mitochondrial effects occur at higher concentrations (5). However, the
concentrations in our experiments are in line with tumor intracellular levels, and we used
PBS as a diluent, which yields greater DNA binding capacity and, in turn, cytotoxicity
(18). Despite the lack of effect on mitochondrial content/ROS production, these data
nonetheless reinforce the potential myotoxic effects of chemotherapeutics through
multiple pathways.

Several limitations to our studies deserve note. First, all patients received short courses of
dexamethasone concurrent with their chemotherapy (1 to 4 days for each cycle,
depending on symptom severity). Glucocorticoids have well-known effects to cause
muscle atrophy (53). Whether the short course of dexamethasone given to these patients
would affect muscle structure or function is not known, but longer-term treatment with
glucocorticoids combined with bed rest (28 days) lead to only modest changes in muscle
fiber size (~11% reductions in cross-sectional area; (19)) and chronic treatment has
minimal effects on mitochondrial content (28). Moreover, the atrophic effects of
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glucocorticoids are generally more apparent in fast-twitch, MHC II fibers (53), whereas
we found effects in both fiber types. Thus, we conclude that it is unlikely that
glucocorticoids alone explain the muscle atrophy or mitochondrial rarefaction that we
observed in breast cancer patients, but acknowledge that current data is insufficient to
resolve what effects it might have. Second, because of the cross-sectional nature of our
study, we cannot discount that muscle phenotypes observed in cancer patients are
attributable to other factors separate from, or secondary to, cancer and its treatment. For
example, acute (e.g., following surgical resection) or chronic physical inactivity (40),
which can also induce muscle atrophy and mitochondrial adaptations, may explain these
differences. During the review and revision of our manuscript, a study was published
showing declines in skeletal muscle fiber size and citrate synthase activity over 16 weeks
in breast cancer patients receiving chemotherapy (41), suggesting that muscle atrophy
and mitochondrial adaptations occur in concert with cancer treatment. Third, controls
were slightly older than cancer patients. However, most of the phenotypes noted in
cancer patients (e.g., fiber atrophy, mitochondrial rarefaction) would worsen with aging,
suggesting that the age difference likely lessened group differences in these measures.
Fourth, myotube cultures are not a perfect model of in vivo skeletal muscle. While they
offer a model system to evaluate the singular effects of select agents and obviate offtarget effects found in vivo (e.g., cardiac damage/failure associated with DOX
administration (26) could affect skeletal muscle size and function (54)), they do not
recreate the 3D structural or functional environment of in vivo muscle. Nonetheless,
numerous aspects of the atrophic process have been studied extensively in myotube
cultures and been shown to correspond with skeletal muscle in vivo, such as the effects of
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cancer to promote oxidant stress (7, 39). Fifth, we did not include a group of postresection, treatment-naïve patients to further delineate the effects of chemotherapy
because of practical difficulties in recruiting and studying these patients. Finally, we did
not standardize for time on chemotherapeutics among patients, although it did not
correlate with any outcomes that differed between groups.

In summary, our results provide evidence for skeletal muscle atrophy and mitochondrial
rarefaction in breast cancer patients that may be linked to the mitotoxic effects of
chemotherapeutics. From a clinical standpoint, these adaptations may contribute to
muscle weakness (atrophy) and fatigue (mitochondrial). Accordingly, that
chemotherapeutics have such effects on skeletal muscle provides a possible explanation
for the high prevalence of fatigue and functional disability across cancer types (12),
including those not typically characterized by cachexia, such as breast cancer. Given the
contribution of these side effects to a poor quality of life (8) and increased mortality (6, 9,
60), interventions designed to counter these effects on muscle may help to alleviate some
of the burden of the disease on patients.
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Figures and tables

Figure 3.0.1: Breast cancer patient skeletal muscle
morphology.
Figure 1. Skeletal muscle fiber cross-sectional area (CSA) in all fibers and myosin heavy
chain (MHC) I and II fibers (A), myonuclei content in MHC I and II fibers (B),
myofilament fractional area (C) and MHC and actin protein content in tissue homogenates
(D) in controls (open bars) and breast cancer patients (gray bars). Data are mean ± SEM,
with individual data points shown with each bar. For panels A, B and C, multiple
observations within each individual were averaged to provide a single data point for each
volunteer. Representative immunohistochemical images used to measure CSA and
myonuclei content for control and cancer patients are shown above panels A and B,
respectively. Scale bars=100 µm. Representative electron microscopy images used to
measure myofilament fractional area (Panel C) for controls and cancer patients are shown
above panels C and D, respectively. Scale bars=1 µm. AU, arbitrary units. *, P≤0.05; †,
0.07.
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Figure 3.0.2: Breast Cancer patient mitochondrial morphology.
Figure 2. Skeletal muscle mitochondrial (Mito) content and structure in the
intermyofibrillar (IMF) and sub-sarcolemmal (SS) compartments. Representative images
for IMF mitochondrial fractional area for controls and cancer patients are shown above
panels A and B, respectively, with average IMF mitochondrial fractional area (A) and
average size (B) for controls (open bars) and breast cancer patients (gray bars).
Representative images for SS mitochondria for controls and cancer patients are shown
above panels C and D, respectively, with average SS fractional area (C) and average
number (n) per unit sub-sarcolemmal area (D). Scale bars= 1 µm for all images. Data are
mean ± SEM, with individual data points shown with each bar. For panels A-D, multiple
observations within each individual were averaged to provide a single data point for each
individual. *, P<0.05 and **, P<0.01 compared to controls.
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Figure 3.0.3: Patient and C2C12 PRX3.
Figure 3. Relationship of mitochondrial oxidant stress to myofiber size and chemotherapy
administration. The relationship of MHC I (A) and MHC II (B) CSA to peroxiredoxin 3
(Prx 3) expression, and MHC II CSA (C) to oxidized Prx 3 in breast cancer patients (black
squares). The r-value in A is a Pearson coefficient, while r-values in B and C are Spearman
rank coefficients. For panels A and B (n=9) and C (n=11). Effects of 3 days of doxorubicin
(DOX; 0.2 µM) or paclitaxel (TAXOL; 40 nM) treatment (gray bars) vs. control (Ctrl;
DMSO; open bar) on C2C12 myotube Prx 3 expression (D, n=4/condition) and oxidation,
with the latter being shown by Prx 3 dimers (oxidized) under non-reducing conditions, as
shown in the blot in panel E. Quantitation of oxidized Prx 3 is shown in F (n=4/condition).
Data in D and F are mean ± SEM, with individual data points shown with each bar. For
panels A-C, multiple observations for CSA within each individual were averaged to
provide a single data point for each individual. For panel D, immunoblots are shown above
average data with loading control (GAPDH). Loading controls were not shown for panel
E, as oxidized Prx 3 data are expressed as a fraction of total (oxidized + non-oxidized) Prx
3. *, P<0.05 compared to control conditions.
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Figure 3.0.4: Tubulin content in breast
cancer patients and C2C12.
Figure 4. α-tubulin (α-tub) and detyrosinated (deTyr) tubulin expression. α-tubulin and
detyrosinated tubulin were assessed following 3 days of treatment of C2C12 myotubes (A)
with vehicle (CTRL; treated with DMSO; clear bars; n=6) or TAXOL (40 nM; gray bars;
n=6), and in controls (open bars; n=11) and breast cancer patients (gray bars; n=9)(B). Gels
images are provided for both experiments. Data are mean ± SEM, with individual data
points shown with each bar. *, P<0.05 and **, P<0.01 compared to controls.
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Figure 3.0.5: Mitochondrial anti-oxidant administration
on myosin content.
Figure 5. Chemotherapeutic effects on myotube myosin content. The effects of 3 days of
DOX (0.2 µM) or TAXOL (40 nM) administration (gray bars) versus vehicle (DMSO in
both; CTRL; open bars) on myosin content (A) and ROS production (B), with
representative images of myotubes for each experimental condition in panel A shown
above (scale bar for all images=100 μm).The effects of concomitant treatment with the
mitochondrial-targeted anti-oxidant MitoQ (0.25 µM for DOX and 0.125 µM for TAXOL;
gray bars) to prevent myosin loss with DOX or TAXOL are shown in panels C and D,
respectively, with representative images of myotubes for each experimental condition
shown above (scale bar for all images=100 µm). Data are mean ± SEM, with individual
data points shown with each bar. *, P<0.05 and **, P<0.01 compared to control conditions.
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Figure 3.0.6: Anti-oxidant administration on ROS and
mitochondrial content.
Figure 6. Effect of chemotherapeutics (gray bars) and concomitant treatment with the
mitochondrial-targeted anti-oxidant MitoQ (+MitoQ; 0.25 µM for DOX and 0.125 µM for
TAXOL) on mitochondrial content (B and C, respectively) and oxidant production (D and
E) vs. vehicle control (DMSO; clear bars). Data are mean ± SEM, with individual data
points shown with each bar. Co-localization of MitoTracker (green) and MitoSox (red) in
a C2C12 murine myotube (A). Scale bar=10 μm. *, P<0.05 vs. controls; **, P<0.01 vs.
controls; #, P<0.01 vs. TAXOL.
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Figure 3.0.7: Patient p38 and ERK content.
Figure 7. p38 (A) and ERK1/2 (B) expression and phosphorylation (pp38 and pERK1/2,
respectively) in tissue homogenates from controls (open bars; n=11) and breast cancer
patients (gray bars; n=9). Gels images are provided for both phospho- and total protein, as
well as GAPDH. The ratio measure reflects the ratio of phospho- to total protein. Data are
mean ± SEM, with individual data points shown with each bar.
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Table 3.3. Physical and disease characteristics in patients.
Control

Cancer

12

13

Age (yr)

66 ± 5

57 ± 12 *

Body weight (kg)

67 ± 15

70 ± 13

Height (cm)

164 ± 5

161 ± 8

Fat mass (kg)

24 ± 12

28 ± 11

Fat-free mass (kg)

40 ± 5

40 ± 4

15.2 ± 1.3

15.4 ± 1.6

Leg fat-free mass (kg)

13 ± 2

14 ± 2

Cancer Stage (I/II/III)

NA

7/2/4

Histology (n)
Adenocarcinoma

NA

13

Dexamethasone (n)

NA

13

Chemotherapeutics (n)
Taxanes

NA

13

Cyclophosphamide

NA

8

Doxorubicin

NA

5

Trastuzumab

NA

3

History of smoking (n)

NA

1

Radiation (n)

NA

0

n

Fat-free mass index
(kg/m2)

Data are mean ± SD. * P<0.05. NA, not applicable to control volunteers.
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List of abbreviations

CSA: Cross Sectional Area
DMSO: Dimethyl sulfoxide
DOX: Doxorubicin
EM:

Electron Microscopy

MHC I: Myosin Heavy Chain type I
MHC II: Myosin Heavy Chain type II
Prx 3: Peroxiredoxin 3
ROS: Reactive Oxygen Species
TAXOL: Paclitaxel
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Abstract
Muscle contraction may protect against the effects of chemotherapy to cause skeletal
muscle atrophy and weakness, but the mechanisms underlying these benefits are unclear.
To address this question, we utilized in vitro modeling of contraction and
mechanotransduction in C2C12 myotubes treated with doxorubicin (DOX; 0.2 μM for 3
days). Myotubes expressed contractile proteins and organized these into functional
myofilaments, as electrical field stimulation (STIM) induced intracellular calcium (Ca2+)
transients and contractions, both of which were prevented by inhibition of membrane
depolarization. DOX treatment reduced myotube myosin content, protein synthesis, Akt
(S308) and forkhead box O3a (FoxO3a; S253) phosphorylation and increased muscle
ring fiber 1 (MuRF1) expression. STIM (1 h/d) prevented DOX-induced reductions in
myotube myosin content and Akt and FoxO3a phosphorylation, as well as increases in
MuRF1 expression, but did not prevent DOX-induced reductions in protein synthesis.
Inhibition of myosin-actin interaction during STIM prevented contraction and the antiatrophic effects of STIM without affecting Ca2+cycling, suggesting the beneficial effect
of STIM derives from mechanotransductive pathways. Further supporting this
conclusion, mechanical stretch of myotubes recapitulated the effects of STIM to prevent
DOX suppression of FoxO3a phosphorylation and upregulation of MuRF1. DOX also
increased reactive oxygen species (ROS) production, which led to a decrease in
mitochondrial content. While STIM did not alter DOX-induced ROS production or antioxidant gene expression, PGC-1α expression was induced and mitochondrial loss
prevented. Our results suggest that the activation of mechanotransductive pathways that
downregulate proteolysis and preserve mitochondrial content can protect against the
atrophic effects of chemotherapeutics.
Keywords: cachexia, exercise, mechanotransduction
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Introduction
Cancer afflicts ~1 in 2 men and 1 in 3 women (24). With improved detection and
treatments, and increased incidence due to an aging populace (51), the number of
individuals living with effects of cancer and its treatment will exceed 18 million by 2020
(9) and continue to grow. Cancer and its treatment have profound effects on skeletal
muscle, including atrophy, impaired contractility and oxidative dysfunction (54, 55, 57),
that negatively impact quality of life, treatment decisions and survival (4, 6, 10, 41) and
can persist for years after treatment (35). These detrimental effects reduce quality of life
and predispose to disability and cardio-metabolic disease.
Exercise can mitigate the negative effects of cancer and its associated treatment and
improve long-term prognosis (21, 25, 56). Part of these benefits may derive from the
positive effect of exercise on skeletal muscle. Exercise induces an array of beneficial
adaptations in muscle, including improved proteostasis, energy metabolism and
contractility (3, 13). Although the effects of various exercise regimens have been
examined in patients (1, 29, 38), the mechanism(s) whereby exercise derives its benefits
remains unknown. Knowledge of the fundamental mechanisms underlying the benefits of
exercise could inform the development of more effective regimens that derive the greatest
benefit with the least burden on patients. Therefore, we utilized in vitro exercise
modeling in C2C12 myotube cultures subjected to chemotherapeutic treatment, with or
without electrical field stimulation (STIM), to dissect the mechanisms underlying the
beneficial effects of exercise on skeletal muscle. We hypothesized that STIM imparts its
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beneficial effects, in part, via mechanotransductive signaling to upregulate protein
synthesis and preserve mitochondrial health following chemotherapy application.
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Methods
Cell culture. C2C12 myoblasts (ATCC® CRL-1772™, Manassas, VA) were cultured in
growth media (GM), consisting of low glucose (1 g/L), Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Gibco™ Thermo
Fisher Scientific Waltham, MA) and antibiotics (50 U/ml penicillin and 50 μg/ml
streptomycin). Cells were plated (2 X 104 cells/cm2) on Matrigel (60 μg/cm2; Corning,
Bedford, MA) and switched to differentiation medium (DM) of low serum (1% heatinactivated FBS), high glucose (4.5 g/L) DMEM when they reached 90-100%
confluence, as described (36), with modifications as described (18). On day 7 postdifferentiation (d7), myotubes were treated with doxorubicin (DOX) (0.2 μM) or vehicle
control (DMSO in DM) for 3 d (chronic experiments). Thirty minutes after starting DOX
treatment, STIM was applied using a C-Pace pulse generator (20V, 1Hz, 12ms; C-Pace
100, IonOptix, Milton MA) for 1 h each day for 3 days. At the end of each STIM bout,
myotubes were washed twice with Hank’s buffered salt solution (HBSS), fresh DM
containing either DOX or vehicle (DMSO) were added and 23 h allowed before the next
bout of STIM or measurements. In some experiments, myotubes were treated with
tetrodotoxin (TTX; 10µM), a sodium channel inhibitor, or N-benzyl-p-toluene
sulphonamide (BTS; 50µM), an inhibitor of myosin-actin ATPase cycling (49), during
the 1 h STIM bouts. Cells were lysed and collected on d10, 23 h after the last STIM bout,
to eliminate the possibility that results reflect an acute effect of the STIM intervention. In
acute experiments, cells were treated with vehicle, DOX alone, STIM or STIM+DOX, as
described above, to examine acute modulation of protein synthesis, expression of
proteolytic mediators and signaling molecular phosphorylation, and harvested/measured
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after 1 or 24 h. In another set of acute experiments, cells were treated with vehicle, DOX,
cisplatin (CIS; 10 µM) or paclitaxel (TAXOL; 40 nM) without STIM, and harvested after
24 h.
A separate set of acute experiments examined the effects of mechanical stretch on C2C12
myotubes differentiated on type I collagen coated (Advanced Biomatrix, San Diego, CA)
silastic membranes (GLOSS/GLOSS, 0.02 in, Specialty Manufacturing, Saginaw, MI).
Silastic membranes were mounted on two friction-fit C-clamps, as previously described
(14). The screw nuts were set to 30 cycles from baseline when the stretching device was
assembled, as described (14). C2C12 myoblasts were suspended (∼1 × 106cells/ml) and
plated onto silastic membranes (∼1.5–2 × 105 cells/stretching device). The cells were
grown to ∼95% confluence and differentiated into myotubes using 2% horse serum.
After 5 days of differentiation, cells were treated with DOX (0.2 μM) or vehicle control
(DMSO in DM). A 5% stretch was supplied for a duration of 1 h and in cells receiving
DOX, stretch was started 30 min following the first DOX administration, identical to
STIM intervention detailed above. Following 1 h, of stretch the membranes were returned
to baseline, cells washed 2x with HBSS, replaced with the fresh media with or without
DOX for a duration of 23 h, when cells were lysed and collected, as described above.
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Myotube size. Myotube size was assessed from myotube diameter measurements. Digital
images of myotube cultures were acquired at 4X magnification. Average diameters (5
diameters per tube) of n=5 to 25 myotubes per field from n=4 random fields were
measured using Image J software (NIH, Frederick, MD, USA) by an assessor blinded to
treatment status.

Immunocytochemistry. Myofilament proteins were visualized by immunocytochemistry.
Cells were grown on Matrigel-coated (60 μg/cm2), 35 mm, glass bottom imaging dishes
(MatTek; Ashland, MA) or plastic, as detailed above, with the modification that the
media was changed daily. Cells were fixed with 4% paraformaldehyde (Fisher Scientific,
Atlanta, GA), permeabilized with 0.2% Triton-X 100 (Fisher) and blocked with 5% BSA
in PBS for 1 h at room temperature. Cells were incubated overnight at 4°C in fast skeletal
muscle myosin antibody (1:500; MY-32; Sigma) followed by secondary antibody (1:100
anti-mouse IgG, Molecular Probes) to visualize myofilaments, or 1 μM TRITCphalloidin (Sigma) to stain actin to visualize the entire cell. Cells were imaged using a
Nikon Ti-E Inverted Microscope with C2 Confocal at 40X for myofilament measures or
an Olympus BX51 with Q-Imaging Retiga R6 at 10X.

Measurement of contractility and Ca2+ cycling. Ca2+ transients were recorded from d7d10 myotubes grown on Matrigel-coated (60 μg/cm2), 35-mm, glass bottom imaging
dishes (MatTek; Ashland, MA). For these experiments, cells were plated at a higher
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density (2.5 X 104 cells/cm2) and DMEM changed daily. C2C12 myotubes were loaded
with 1 µM Fluo-2-acetoxymethyl ester (Fluo-2 AM, TefLabs, Austin, TX) for 15 min at
37°C in the dark. Cells were washed once with HBSS and placed in pre-warmed DM for
10 min. The culture dish was fitted with a custom-built insert that maintained media
temperature at 37°C and contained platinum electrodes to allow STIM with biphasic
pulses (20V, 1Hz, 12ms) (Myopacer, IonOptix, Westwood MA). The same experimental
design used for performing intracellular Ca2+ recordings was applied to contractility
measurements. Fluorescent signal and cell contractility were traced using an IonOptix
system, as previously described (58). Ca2+ fluorescence was recorded with an inverted
fluorescence microscope and galvo-controlled, dichroic mirror filters at 480/510 nm
(Hyperswitch, IonOptix) (44). Contractions were tracked using the edge detection feature
of the IonWizard data acquisition software using visible landmarks on/within the
myotube. Both contraction and Fluo-2 AM fluorescence measurements were made
simultaneously from the same myotube. Experiments lasted 300 sec. Transient analysis
was performed using the IonWizard analysis software (IonOptix). For each test condition,
data for 15-20 seconds of Ca2+ transients or contractions per myotube were averaged,
using the pacing time as a common reference point, to derive an averaged monotonic
Ca2+/contractility transient. Fractional change, which indicates the percentage of peak
following STIM relative to baseline, was used to quantify contractile dynamics and Ca2+
transients. Images of the Ca2+ fluorescent signal were acquired (40 frames/sec) using a
spinning disk confocal microscope (Yokogawa CSU-W1). During these experiments,
cells were stimulated (20V, 1Hz, 12ms) with platinum electrodes.
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An additional set of experiments were performed without the measurement of Ca2+
fluorescence to assess contractility. To aid in the visualization of cell movement, 2 μm
latex beads (1:1000, L3030; Sigma) were added to the culture dish 2 h prior to STIM.
Digital video images were collected with a down-sampled field of 512 X 512 pixels2 and
a frame rate of 10 Hz (MyoCam-S3, IonOptix). Video images were analyzed by first
establishing a hexagonal grid and tracking each local image featured within each hexagon
by cross-correlation from frame to frame (Figure 2A, left panel). The displacement of a
local image relative to its neighboring local images allowed for calculation of local strain
(i.e., change in relative displacement between neighbors normalized to the original
distance between neighbors). With each local image having six neighbors, three strains
oriented at 120° to each other were measured. This orientation of strains allowed for
calculation of magnitude and orientation of principal strains on a Mohr’s circle similar to
that based on a delta rosette strain gauge (8). Local strains are depicted as green ellipses
illustrating the contraction or elongation of the local region (Figure 2A, right panel).
From these assessments, relative strain was calculated.
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Myotube mitochondrial content and reactive oxygen species (ROS) production.
Mitochondrial content and ROS production were measured with fluorometric dyes, as
described (18). Briefly, C2C12 myotubes grown in 35 mm dishes or black-walled 96 well
plates were loaded with fluorescent dyes to assess mitochondrial content (1 μM
MitoTracker Green FM; 490/516 nm) and ROS production (1 μM MitoSOX Red;
510/580 nm; both Molecular Probes, Eugene, OR) 15 minutes prior to measurement.
Fluorescence was measured on a microplate reader (BioTek, Winooski, VT) and the
MitoSox signal was expressed relative to MitoTracker signal to control ROS production
for variation in mitochondrial content. We have shown that the MitoSox and MitoTracker
signals co-localize (18).

Protein synthesis. Protein synthesis was measured using the SUnSET technique, as
described (14). Briefly, 23 h after the last bout of STIM, stretch or control conditions, 1
μM puromycin (Sigma) was added to myotubes for 30 min prior to lysis and collection.
Lysates were then analyzed by western blot, as described below.

Protein expression. Protein expression or phosphorylation was measured by western blot.
Myotubes were washed with phosphate buffered saline, lysed (50 mM Tris, 150 mM
NaCl, 10% (v/v) glycerol, 0.5% IGEPAL CA-630,1 mM EDTA, containing Protease
Inhibitor Cocktail (1:100, cat# P8340, sigma) and Phosphatase Inhibitor Cocktail 3
(1:100, cat# P0044, sigma)), incubated on ice for 30 min and then centrifuged at 14,000 ×
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g at 4 °C for 10 min. Lysate protein contents were measured (BioRad DC Protein Assay,
Hercules, CA) and diluted in gel loading buffer. Proteins were separated by SDS-PAGE
(Bio-Rad, Hercules, CA, USA), transferred to polyvinylidene (PVDF) membranes and
blocked with Tris-buffered saline-Tween buffer (TBST; 150 mM NaCl, 0.05 % Tween20, and 20 mM Tris-HCl, pH 7.4) containing 5% non-fatty milk or BSA. After blocking,
membranes were incubated overnight with primary antibody: anti-puromycin, clone
12D10 (1:2000, Millipore MABE343, RRID:AB_2566826), myosin (1:20000,Sigma
M4276, RRID:AB_477190), TRIM63/muscle ring finger 1 (MuRF-1; 1:1000, R&D
Systems AF5366, RRID:AB_2208833), phospho-p70 S6 kinase (T389; 1A5; 1:1000,
Cell Signaling Technology 9206, RRID:AB_2285392), p70 S6 kinase (1:1000, Cell
Signaling Technology 2708, RRID:AB_390722), phospho-AMPK-alpha (T172, 1:2000,
Cell Signaling Technology 2535, RRID:AB_331250), AMPK (1:2000, Cell Signaling
Technology 23A3, RRID:AB_490795), phospho-Akt (T308, 1:1000, Cell Signaling
5056, RRID:AB_10695743), Akt (1:1000, Cell Signaling Technology 4691,
RRID:AB_915783), phospho-FoxO3a (S413, 1:1000, Cell Signaling Technology 8174,
RRID:AB_10889562), phospho-FoxO3a (S253, 1:1000, Cell Signaling Technology
9466, RRID:AB_2106674), FoxO3a ( 1:1000, Cell Signaling Technology 2497,
RRID:AB_836876). Membranes were washed for 30 min in TBST and then incubated for
1 h at room temperature in 5% milk-TBST containing secondary antibody. For
puromycin measurements, the entire lane was quantified by densitometry.
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RNA isolation and quantitative real-time PCR (qPCR). Total RNA was isolated from
C2C12 cells using Trizol reagent followed by a chloroform-isopropanol extraction
(Invitrogen, USA), and the concentration and quality measured using a NanoDrop 2000
spectrophotometer (Thermo Fisher, Waltham MA). cDNA was synthesized from 100 ng
of mRNA using the qScript Supermix reagent kit per manufacturer’s instructions
(Quantabio, Beverly, MA). Quantitative real-time PCR (qPCR) was performed using
iTaq™ Universal SYBR® Green Supermix (BioRad, Hercules, CA) on a CFX96 Touch
system (BioRad, Hercules, CA), with the relative mRNA expression calculated using the
Ct (2−ΔΔCt) method normalized to GAPDH expression. Primer sequences are provided
in Table 1.

Statistics. One- or two-way analysis of variance (ANOVA) models were used to examine
differences between groups. For one-way ANOVA, time, pharmacological inhibitor of
contraction (e.g., BTS or TTX) or chemotherapy were utilized as between group factors.
In two-way ANOVA, chemotherapy and STIM/stretch/time were used as between-group
factors. If an interaction effect was noted, pairwise comparisons (Least Significant
Difference) were performed to identify the location of group differences. Relationships
between variables were determined by linear regression analysis. All data were analyzed
using GraphPad Software (v7; La Jolla, CA) and are presented as mean ± standard error
of the mean (SEM), unless otherwise stated.
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Results
Characterization of C2C12 myotubes and STIM. C2C12 myotubes were differentiated
for 7 days before treatment with chemotherapy and/or STIM was started. Under our
culture conditions, there was a rapid growth and accumulation of myosin between d5 and
d7 (Figure 1A and B), followed by myosin content and myotube size reaching a plateau.
At d7, myotubes express myofilament proteins, such as myosin (Figure 1A and 1C), actin
(Figure 1A) and α-actinin (data not shown), and organize these proteins into
myofilaments (Figure 1C). These myofilaments are functional, as are other components
of the excitation-contraction coupling system, as STIM of d7 myotubes provokes
intracellular Ca2+ cycling (Figure 1D, 1E and 1F; Supplemental Video 1) and contraction
(Figure 1E and 1F; Supplemental Video 2). Moreover, calcium release and reuptake were
synchronized with the electric pulses, and with contraction and relaxation of the myotube
(Figure 1E), respectively. Finally, the degree of fractional shortening tracked with the
magnitude of the intracellular Ca2+ transient (Figure 1F).
Myotube contractility was quantified using two techniques. The first involved manual
selection and automated tracking of two cellular landmarks on myotubes using the edge
tracking feature of the IonWizard software. Data from these measurements showed that
myotubes contracted with a fractional strain of 3.9 ± 2.7% (n=13 myotubes; open circles
in Figure 2C). These measurements, however, suffer bias from manual selection of
landmarks and limitations in the precision of edge tracking. To address these limitations,
we developed a novel pixel tracking image analysis approach (Figure 2A and 2B) that
minimizes these biases. This approach yielded a slightly lower average fractional strain
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of 2.6% ± 1.0 (n=17 myotubes; filled circles in Figure 2C). Each technique has strengths
and weaknesses, but their results generally agreed. Thus, we calculated an average
fractional strain from all data, which was 3.2 ± 2.0% (Figure 2C).
Myotube contraction with STIM was sensitive to modulators of excitation-contraction
coupling (ECC) and myosin-actin cycling. Application of the Na+ channel blocker TTX,
which prevents membrane depolarization and all downstream ECC events, eliminated
myotube intracellular Ca2+ cycling (P<0.05) and contraction (P<0.01; Figure 2D and
Supplemental Figure 2A). Additionally, application of BTS, an inhibitor of myosin-actin
interaction/ATPase activity, eliminated contraction (P<0.01) without diminishing Ca2+
cycling (Figure 2D and Supplemental Figure 2B).

STIM prevents DOX-induced myosin loss. A DOX by STIM interaction effect (P<0.01)
was observed for myosin content, such that DOX caused a reduction in myosin content
(P<0.01), whereas 1 h of STIM each day during DOX administration prevented loss of
myosin (Figure 3A). STIM alone did not alter myotube myosin content relative to
control. To confirm that STIM-induced membrane depolarization and subsequent
intracellular Ca2+ cycling and contraction were required for this protective effect of
STIM, we treated myotubes with TTX, as this eliminates intracellular Ca2+ cycling and
contraction (Figure 2D and Supplemental Figure 2A). Treatment with TTX prevented the
effects of STIM on myosin content (Figure 3B; P<0.01 DOX effect).
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DOX and STIM effects on protein synthesis and proteolytic mediators. To examine the
mechanism by which STIM prevented DOX-induced myosin loss, we measured acute (1
d) modulation of protein synthesis and expression of MuRF1, an E3 ubiquitin ligase
responsible for ubiquitination of myosin (7). DOX treatment reduced protein synthesis
rate (Figure 3C and 3D; P<0.01 DOX effect) and phosphorylation of p70S6 kinase
(T389; Figure 3E; P<0.01 DOX effect), and STIM was unable to preserve either protein
synthesis or p70S6 kinase phosphorylation in DOX-treated cells (Figure 3C, 3D and 3E,
respectively).
A DOX by STIM interaction effect was noted for MuRF1 expression (P<0.01), such that
DOX increased MuRF1 protein (P<0.01) and STIM prevented the DOX-induced increase
in MuRF1 expression, while STIM alone did not alter MuRF1 (Figure 3F). A DOX by
STIM interaction was also noted for FoxO3a phosphorylation (S253) (P<0.01), where
DOX reduced FoxO3a phosphorylation and this reduction was prevented by STIM
(P<0.01), while STIM alone did not alter FoxO3a phosphorylation (Figure 3G). At this
same time point (1 d), STIM reduced Akt phosphorylation (S308; Supplemental Figure
2A, P<0.01 STIM effect), but no DOX or DOX by STIM interaction effects were noted.
Because regulation of Akt may be transitory (45), we explored Akt phosphorylation early
following the first STIM bout (1 h; Figure 3H). At this time point, we found a DOX by
STIM interaction effect (P<0.05). Pairwise comparisons showed that DOX+STIM was
higher than all other groups (all P<0.05, with the exception of P<0.01 for DOX).
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Effects of other chemotherapeutics on protein synthesis and MuRF1 expression. We
explored whether other commonly used chemotherapeutics that cause myotube myosin
loss (18) alter protein synthesis and MuRF1 expression similar to DOX at 1 d posttreatment. Results showed that both CIS and TAXOL upregulate MuRF1 expression
(P<0.01 and P<0.05; Figure 4A) and reduce protein synthesis (P<0.01 for both; Figures
4B and 4C), similar to DOX (P<0.01 for both panels), suggesting a common effect of
numerous chemotherapeutics on myotube protein metabolism.

Role of contraction and cell stretch in mediating effects of STIM. To examine if
mechanical contraction and myotube shortening explain the protective effects of STIM,
we treated myotubes with BTS, an inhibitor of myosin-actin interaction that prevents
myotube contraction, but does not disrupt intracellular Ca2+ cycling (Figure 2D and
Supplemental Figure 2B), during 1 h STIM sessions. BTS blocked the effect of STIM to
prevent DOX-induced myosin loss over 3 d of treatment (Figure 5A; P<0.01 DOX
effect). To clarify whether the effects of STIM were mediated via mechanotransductive
signaling, we mechanically stretched cells (5%) for 1 h during DOX or vehicle
treatments. The magnitude of the stretch stimulus was chosen to match the relative strain
of myotubes induced by STIM (Figure 2C). DOX by stretch interaction effects were
found for MuRF1 (P<0.01) and FOXO3a (S253; P<0.05). Pairwise comparisons showed
that, similar to STIM experiments (Figure 3), DOX stimulated MuRF1expression (Figure
5B; P<0.01) and reduced FoxO3a phosphorylation (S253; P<0.05; Figure 5C), and
mechanical stretch prevented these alterations (Figure 5B and 5C). Stretch alone did not
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alter MuRF1 expression or FoxO3a phosphorylation. In contrast to STIM, however,
mechanical stretch remediated DOX-induced reductions in protein synthesis (Figures 5D
and 5E; P<0.01 DOX by stretch interaction). These changes in protein synthesis were
generally paralleled by altered p70 S6K phosphorylation of (Figure 5F), but the
interaction effect was not significant (P<0.01 stretch effect and P<0.01 DOX effect).

Activation of TRPV1 with CAP does not mimic effects of STIM on myotube myosin
content. Recent work identified activation of TRPV1 channels as integral to the muscle
anabolic response to mechanical stimuli, that the anabolic response to stress was
mimicked by the TRPV1 agonist CAP and that CAP could prevent the catabolic effects
of unloading and denervation (26). Because the effects of STIM were dependent on
myotube contraction (i.e., mechanotransduction; Figures 3B and 5A) and were mimicked
by cell stretch (Figure 5B and 5C), we reasoned that CAP administration may mimic the
effects of STIM. Initially, we performed a dose-response experiment to examine the
effects of CAP (50 nM to 1 µM) for 3 d (d7-d10) on myotube myosin content. To our
surprise, we found no effect of CAP on myosin content at any concentration. We chose a
dose of 100 nM CAP because prior work showed that this was sufficient to activate
anabolic pathways (e.g., p70S6 kinase; (26)). CAP (100 nM) did not mitigate the effect of
DOX administration to reduce myotube myosin protein content (Figure 6B). To further
interrogate whether a higher dose of CAP could mimic mechanotransductive signaling
and protect against DOX-induced atrophy, we also treated cells with 1 μM CAP.
However, this higher dose of CAP similarly did not mitigate the effects of DOX to reduce
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myosin content (Figure 6C). Finally, 100 nM CAP showed a DOX by CAP interaction
effect (P<0.01) on ROS production, but not with directionality that would be expected to
mitigate myotube myosin loss. DOX increased ROS production (P<0.01), with an
additive effect when combined with CAP (Supplemental Figure 3A). We found an effect
of DOX (P<0.01) to reduce mitochondrial content regardless of CAP treatment
(Supplemental Figure 3B).

Myotube mitochondrial ROS production, content and antioxidant gene expression. As
the TRPV1 agonist CAP did not mitigate the effects of DOX, we sought other potential
mechanisms underlying the protective effects of STIM on myotube myosin content. We
recently showed that DOX treatment for 3 d increased myotube mitochondrial ROS
production and reduced mitochondrial content, and that mitochondrial targeted antioxidant treatment prevented DOX-induced ROS production, mitochondrial loss and
reductions in myotube myosin content (18). As exercise modulates mitochondrial biology
and redox balance, we examined the effects of STIM on DOX-induced changes in
mitochondrial content, ROS production, and antioxidant gene expression. One day of
DOX treatment increased ROS production, and these effects were maintained after 3 d of
DOX treatment (Figure 7A; P<0.01 DOX effect). Unlike ROS production, 1 d of DOX
treatment did not reduce mitochondrial content, whereas a reduction (P<0.01) was
apparent after 3 d of DOX treatment (Figure 7B; P<0.01 DOX by time interaction; 3d
Control vs. 3 d DOX; P<0.05).
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A STIM by DOX interaction effect was found on ROS production (P<0.01), such that
STIM did not prevent DOX-induced upregulation of ROS production at 3 d (Figure 7C).
In fact, both STIM groups showed increased ROS production at 3 d compared to nonSTIM groups (P<0.01; Figure 7C). DOX alone also increased ROS production (P<0.01).
A STIM by DOX interaction was noted for mitochondrial content (P<0.05), as STIM
prevented DOX-induced reductions in mitochondrial content (Figure 7D). This effect of
STIM to preserve mitochondrial content was accompanied by increased expression of
PGC-1α (P<0.05 STIM effect; Figure 7E), although no effect of STIM was noted on
TFAM expression. DOX upregulated TFAM expression (P<0.01 DOX effect).
Energetic insufficiency brought about by DOX-induced mitochondrial loss could
contribute to myosin loss via upregulation of AMPK and activation of FoxO3a/MuRF1
(43). In this context, the protective effects of STIM could derive from its ability to
maintain mitochondrial content (Figure 7D). To explore this possibility, we evaluated
AMPK (T172) and FoxO3a (S413) phosphorylation 1 h and 1 d following the start of
treatments. We found no DOX or DOX by STIM interaction effects on AMPK
phosphorylation after 1 h (1.5 h post-DOX/1 h post STIM; Supplemental Figure 4A), but
there was a STIM effect (P<0.05) 1 d following the start of treatments (Figure 7F). Thus,
the pattern of AMPK phosphorylation did not match the pattern of changes in
mitochondrial content (Figure 7D) or MuRF1 expression (Figure 3F). Interestingly,
however, we found that FoxO3a phosphorylation at S413, a site phosphorylated by
AMPK (17), 1 d following the start of treatments showed a strong trend (P=0.06) towards
a DOX by STIM interaction effect. Pairwise comparisons showed that there was an
increase (P<0.05) in FoxO3a phosphorylation with DOX and that STIM prevented this
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increase. To further examine mechanosensitive control of FoxO3a, we examined the
effect of mechanical stretch on this phosphorylation site at 1 d post-treatment and found a
DOX by stretch interaction effect (P<0.05; Figure 7H). DOX increased FoxO3a
phosphorylation relative to control and stretch control (P<0.01 and P<0.05, respectively).
However, stretch did not fully remediate the increase in FoxO3a phosphorylation. In fact,
FoxO3a phosphorylation was increased in the DOX + Stretch group compared to control
(P<0.05).
Finally, we examined whether STIM upregulated antioxidant gene expression, as recent
studies have suggested this possibility (22), and because we previously showed that
mitochondrial targeted anti-oxidant prevents myotube myosin loss with DOX
administration (18). DOX (P<0.05) and STIM (P<0.01) effects were found for expression
of the redox-sensitive transcription factor Nrf2, while no effects were observed for
KEAP1 (Figure 8A). DOX effects were observed for a number of antioxidant genes,
including SOD1, SOD2, CAT and GCLM (all P<0.01). DOX by STIM interaction effects
(both P<0.05) were found for GCLC and GPx1. In the former, DOX increased GCLC
expression relative to all other groups (P<0.05 to P<0.01). In the latter, DOX increased
GPx1 expression relative to all other groups (P<0.05). There were no effects of STIM
observed for any gene, nor any DOX by STIM interaction effects.
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Discussion
How muscle contraction protects skeletal muscle against the detrimental effects of
chemotherapeutics (33, 40, 52, 53) is unclear. Using in vitro muscle contraction models,
we show that the atrophic effects of DOX can be prevented by daily bouts of electricallyinduced contraction. STIM prevented DOX-induced downregulation of Akt and FoxO3a
phosphorylation and increased MuRF1 expression, but was unable to recover protein
synthesis. STIM effects were mediated via mechanotransductive signaling, as
pharmacological inhibition of myosin-actin interaction/ATPase abolished these effects
and mechanical stretch mimicked the effects of STIM. Finally, STIM upregulated PGC1α and prevented the loss of mitochondrial content. Our findings suggest that muscle
contraction counters the catabolic effects of chemotherapy through effects to
downregulate proteolysis and preserve mitochondrial content via mechanotransductive
signaling pathways.
Contrary to our original hypothesis, the most likely mechanism to explain the beneficial
effects of STIM is reductions in proteolysis, as STIM downregulated DOX-induced
increases in MuRF1 expression, while protein synthesis was not rescued. How STIM
modulates MuRF1 expression is suggested by Akt and FoxO3a phosphorylation data.
Prior studies show that muscle stretch and contraction upregulate Akt activation (45), and
our data advance these results to show that STIM-induced myotube contraction counters
the effects of catabolic mediators, such as DOX, to reduce Akt phosphorylation. FoxO3a
transcriptional effectiveness is regulated, in part, by its cytoplasmic-nuclear localization,
which is regulated via targeted phosphorylation, particularly by Akt (48).
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Correspondingly, increased Akt phosphorylation with STIM was associated with similar
preservation of FoxO3a phosphorylation on the Akt site (S253). The effects of STIM to
prevent DOX-induced increases in MuRF1 further suggest that these signaling events
likely reduced FoxO3a transcriptional activity. Supporting the relevance of our results for
in vivo skeletal muscle are data showing that electrical stimulation of skeletal muscle
prevents disuse-induced atrophy, in part, via downregulation of MuRF1 expression (11).
One strength of our in vitro contraction model is that it allows us to discern whether
STIM mediates these effects via mechano- or Ca2+ chemotransductive signaling
pathways. BTS application during 1 h daily STIM bouts prevented the ability of STIM to
preserve myotube myosin content in the face of DOX, implicating mechanotransductive
pathways in the beneficial effects of STIM. This notion was reinforced by our results
from mechanical stretch experiments, which showed similar upregulation of FoxO3a
phosphorylation and decreased MuRF1 expression. These findings concur with studies
showing that muscle stretch upregulates Akt (2) and reduces nuclear FoxO content and
DNA binding (39). Such a mechanism may be operative in vivo, as recent studies show
that muscle stretch diminished atrophy associated with and experimental intensive care
unit stay via downregulation of MuRF1 expression, whereas it did not alter protein
synthesis (42). Collectively, these data extend the role of muscle mechanotransductive
signaling to include protection against catabolic stimuli, and suggest that this occurs
through suppression of proteolysis, rather than preservation or upregulation of protein
synthesis (59).
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Building on this last point, although we attempted to match mechanical stretch to STIM
by utilizing a similar relative strain, the two stimuli differed with respect to their effects
on protein synthesis. Unlike STIM, stretch prevented the DOX-induced reduction in
protein synthesis. The more pronounced effects of stretch on myotube protein synthesis
may relate to the fact that the mechanical stretch stimulus (5%) was slightly higher than
the fractional strain during STIM (~3%), as the stretch device has not been validated
below 5%, while the response to ≥5% has been previously established. Additionally,
STIM imparts its mechanotransductive effects through shortening of the cell while stretch
is an elongation stimulus. More specifically, STIM produces stress/strain on myotubes
primarily via shortening along their longitudinal axis (Supplemental Video 1), in-line
with the orientation of myofilaments (Figure 1C). In contrast, the uniaxial mechanical
stretch model we employed would cause multi-axial lengthening and, in turn,
stress/strain, because myotubes grow in random orientations relative to the axis of stretch.
This may explain differences between the two stimuli, as transverse stretch is more
anabolic than uniaxial stretch (23, 34). Extrapolating from these results, one might
hypothesize that a more intense mechanical stimulus than that provided by STIM may
more effectively counter the deleterious effects of DOX by also preserving protein
synthesis (59). Regardless of differences between STIM and stretch conditions on protein
synthesis, the similarity in their ability to prevent DOX-induced modifications in
Akt/FoxO3a/MuRF1 signaling underscores the importance of exercise-induced
downregulation of proteolysis in prevention of chemotherapy-induced atrophy via
mechanotransductive pathways.
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Numerous mechanotransductive-signaling pathways could mediate the effects of
STIM/stretch. We chose to examine the effect of TRPV1 antagonism with CAP because a
recent report suggested that activation of TRPV1 with CAP promoted muscle anabolism
and was sufficient to prevent unloading- and denervation-induced atrophy (26, 27).
Moreover, activation of TRPV1 channels by CAP increases mitochondrial content and
function in C2C12 myotubes and mouse muscle in vivo (37). However, we found that
treatment of myotubes with CAP did not prevent DOX-induced atrophy, nor did it
counter DOX-induced oxidant production or mitochondrial loss. Although we used a
concentration of CAP (100 nM) shown to promote muscle anabolism/anti-catabolism (26,
27) and mitochondrial adaptations (37), higher concentrations (1 µM) similarly failed to
prevent DOX-induced myosin loss. In fact, we found no evidence for effects of CAP on
myotube myosin content throughout a range of doses. Thus, our results do not support the
contention that the beneficial effects of STIM in our model are mediated via
mechanotransductive signaling through activation of TRPV1 channels via CAP.
In light of the role for mitochondrial oxidant production and/or rarefaction in the
deleterious effects of DOX and the protective effects of reducing oxidant stress (18), we
examined whether the effects of STIM are explained by effects on mitochondrial
health/redox balance. STIM preserved mitochondrial content, an effect accompanied by
increased PGC-1α expression, a key mediator of mitochondrial biogenesis that is
upregulated in response to muscle contraction and that protects against disuse-induced
mitochondrial loss and atrophy (32, 47). In keeping with studies overexpressing PGC-1α
(5, 31), STIM may prevent DOX-induced atrophy, in part, through effects on
mitochondrial dynamics to maintain mitochondria content and/or function. Energetic
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insufficiency brought about by mitochondrial loss would be expected to upregulate
AMPK, which can phosphorylate FoxO3a (17), leading to transcription of MuRF1.
However, the pattern of AMPK phosphorylation (T172) did not mirror the effects of
DOX or STIM on Akt/FoxO3a/MuRF1 activation/expression. Despite this, FoxO3a
phosphorylation on S413, which is regulated by AMPK, was increased by DOX and
reduced to control levels by STIM. In the absence of concordance between AMPK and
FoxO3a phosphorylation, we posit that STIM-induced upregulation of PGC-1α may
contribute to inhibition of FoxO3a S413 phosphorylation and MuRF1 expression (20, 43,
47) and, in turn, myotube myosin loss.
As prior work from our lab and others suggest that improved redox balance prevents the
deleterious effects of DOX (15, 16, 18), the beneficial effects of STIM could also be
explained, in part, by its ability to reduce ROS production and/or increase anti-oxidant
capacity. Contrary to the former possibility, however, STIM did not diminish the DOXinduced increase in mitochondrial ROS production. In fact, in keeping with prior work
(46), STIM-induced myotube contraction increased ROS production (Figure 6C), which
may partially account for the effects of STIM to upregulate Akt (19) and PGC-1α (50).
Additionally, contrary to recent reports (22), our results showed that no effect on
antioxidant gene expression. This may be explained by our milder STIM protocol. In our
model, ROS production was increased ~20% over baseline (Figure 7C), whereas, in
Horie et al. (22), STIM increased ROS production ~100% over baseline. Whether
variation in the magnitude of STIM-induced ROS production explains differences in
antioxidant gene expression, however, is unclear, as DOX alone increased antioxidant
gene expression with a similar, or slightly smaller, increase in ROS production compared
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to STIM alone. There were also differences in the timing of STIM between studies. We
utilized 1 h of STIM, whereas Horie et al. observed an upregulation of antioxidant genes
only after 4 h of STIM. Regardless of the explanation for differences between studies, our
results suggest that the protective effects of STIM are likely not mediated via either
reduced oxidant production or upregulation of antioxidant defenses.
Several limitations of our study should be acknowledged. First, responses in myotube
cultures to STIM and DOX may not emulate skeletal muscle in vivo. However, myotubes
expressed functional myofilaments, contracted in response to STIM and were sensitive to
pharmacological inhibitors of ECC and myosin-actin interaction/myosin ATPase similar
to in vivo muscle. Moreover, adaptations in protein metabolism and signaling were
similar to those demonstrated in vivo in response to DOX and exercise (33), and these
patterns mimicked those in other atrophy models (42) and with the use of electrical
stimulation to protect against atrophy in vivo (11, 12). Thus, while this model has
limitations, it is likely sufficient to study the metabolic and signaling pathways whereby
muscle contraction prevents the deleterious effects of chemotherapeutics. Second, static
mechanical stretch may provoke different cellular responses than the cyclical contracting
myotubes with STIM (28). However, similar results to prevent upregulation of
proteolytic signals via FoxO/MuRF1 were found in both models, implicating
mechanotransductive signaling in the beneficial effects of STIM.
In summary, the beneficial effects of mechanotransductive signaling in C2C12 myotubes
can prevent DOX-induced activation of the FoxO-MuRF1 pathway via downregulation of
Akt activation. These effects of STIM may be mediated, in part, via upregulation of
160

PGC-1α expression, which has been shown to inhibit FoxO3a-induced expression of
MuRF1 (47) and upregulates mitochondrial content. These effects of STIM parallel the
benefits of neuromuscular electrical stimulation (NMES) in humans to prevent atrophy
(12). NMES maintains or improves muscle size and strength in clinical populations (30),
and might be a useful exercise modality in cancer patients during chemotherapy, as they
are often unable to perform facility-based exercise programs because of fatigue or other
logistical/clinical hurdles.
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Figures & Tables

Figure 4.0.1: Myotube morphology and dynamics.

173

Figure 1. C2C12 murine myotube morphology, protein expression, Ca2+ cycling and
contraction. (A) Content and morphology of myotubes at d3, d5, d7, d8.5 and d10 are
shown (scale bar=25 µm; top panels) and following fixation and staining of actin with
TRITC-labeled phalloidin (scale bar=200 µm; middle panels), with corresponding
representative gel bands for fast myosin expression at each time point (bottom panel). (B)
Average myotube myosin (open triangles) expression and diameters (open circles) are
shown for d3 (n=9 and 107), d5 (n=9 and 116), d7 (n=9 and 177), d8.5 (n=9 and 186) and
d10 (n=9 and 146, respectively). Differences between days are denoted with different
letters (all differences are P<0.01 using one-way ANOVA). (C) Myofilament formation in
d7 myotube using anti-fast myosin antibody (green) in d7 myotubes (scale bar=25 µm).
(D) Pseudo colored images of intracellular Ca2+ cycling in d7 myotube measured by Fluo2 AM in response to 20V, 12 ms pulses at 1Hz. Time signatures for each image are
provided at the bottom of each panel (frame rate=40/s, scale bar=10 µm). The time
sequence starts in the upper left corner image, runs from right to left, ending in the bottom
right image. (E) Raw Fluo-2 AM fluorescence signal, showing intracellular Ca2+ release
(+ excursion) and reuptake (- excursion; top panels), and contractions (- excursion) and
relaxations (+ excursion; bottom panels) for several excitation-contraction cycles (left side)
and the average of 15 contraction cycles (right side) in response to 20V, 12 ms pulses at
1Hz. (F) Relationship between the relative magnitude of intracellular Ca2+ cycling and
contraction measures simultaneously in d7 myotubes (n=8)..
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Figure 4.0.2: Myotube contractile dynamics and intracellular Ca2+ cycling.
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Figure 2. Contractile dynamics and intracellular Ca2+ cycling in d7-d10 C2C12 myotubes.
(A) Digital images of C2C12 myotube at rest with hexagonal grid overlay (scale bar=10
µm; left panel). A blowup of the circled hexagon is provided for baseline (Frame 0) and
during the peak of contraction (Frame 17) to illustrate contraction monitoring by pixel
tracking (right panel). Yellow colored ellipses show trackable image contrast, with green
ellipses tracking local pixel strains and negative displacements signifying contractions. (B)
Negative displacements of one hexagonal grid showing several contraction cycles. (C)
Fractional strain of n=30 myotubes measured with edge tracking of manually selected
myotube features/landmarks (open circles) and pixel tracking approach described above
and in the Methods section (closed circles). Data are mean ± SEM, with individual data
points shown. (D) Average fractional change (Δ) in contraction and intracellular Ca2+
cycling under basal conditions (n=14 and 17, respectively), following TTX (n=8 and 7,
respectively) and BTS administration (n=5 and 9, respectively). *, P<0.05 and **, P<0.01
compared to its respective basal conditions using one-way ANOVA.
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Figure 4 0.3: STIM molecular changes.
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Figure 3. Effects of doxorubicin (DOX; 0.2 µM; gray bars) or vehicle (DMSO; CTRL;
open bars) administration, with or without electrical field stimulation (±STIM; 20V, 12 ms
pulses at 1Hz for 1 hr/d), on myotube myosin content, protein synthesis, markers of
proteolysis and signaling molecule expression/phosphorylation. (A) DOX administration
(3 d) reduces myosin content and STIM prevents this reduction (n=12/bar; P<0.01 DOX
by STIM interaction). (B) Application of tetrodotoxin (TTX; 10µM) during 1 h STIM bouts
mitigates its protective effects on myotube myosin content (n=6/bar; P<0.01 DOX effect).
(C) Representative gel image of protein synthesis measurements using incorporation of
puromycin into protein, as described in Methods section, for a sub-set of replicates in 1 d
DOX/STIM experiments. (D) DOX administration (1 d) reduces myotube protein synthesis
and STIM fails to prevent this reduction (n=6/bar; P<0.01 DOX effect and P<0.05 STIM
effect). (E) DOX administration (1 d) reduces phosphorylation of p70 S6 kinase (p-p70S6k;
S308) and STIM fails to prevent this reduction (n=6/bar; P<0.01 DOX effect). (F) DOX
administration (1 d) increases MuRF1 expression and STIM prevents this increase
(n=6/bar; P<0.01 DOX by STIM interaction). (G) DOX administration (1 d) decreased
FoxO3a phosphorylation (p-FoxO3a; S253) and STIM prevents this decrease (n=6/bar;
P<0.01 DOX by STIM interaction). (H) Phosphorylation of Akt (S308) was higher in STIM
+ DOX compared to all groups (P<0.05), except DOX, where P<0.01 (n=6/bar; P<0.05
DOX by STIM interaction). Representative gel images are shown at the top of panels A,
B, E, F, G and H for a subset of replicates. All data are mean ± SEM, with individual data
points shown with each bar. *, P<0.05 and **, P<0.01 in figures to denote either DOX
effects (panels B, D and E) or DOX by STIM interaction effects with a single group
differing from other groups (panels A, F, G and H) using two-way ANOVA.
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Figure 4.0.4: Chemotherapy molecular changes.
Figure 4. Effects of 1 d of administration of common chemotherapeutics: doxorubicin
(DOX), cisplatin (CIS) and paclitaxel (TAXOL), or vehicle (DMSO; CTRL; open bars) on
MuRF1 expression and protein synthesis. (A) All chemotherapeutics increased MuRF1
expression (n=6/bar). (B) Representative gel image of protein synthesis measurements
using incorporation of puromycin into protein, as described in Methods section, for a subset of replicates with chemotherapy administration. (B) Administration of all
chemotherapeutics reduced myotube protein synthesis (n=6/bar). All data are mean ± SEM,
with individual data points shown with each bar. *, P<0.05 and **, P<0.01 compared to
control conditions via one-way ANOVA.
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Figure 4.0.5: Stretch molecular changes.
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Figure 5. Effects of doxorubicin (DOX; 0.2 µM; gray bars) or vehicle (DMSO; CTRL;
open bars) administration, with or without electrical field stimulation (±STIM; 20V, 12 ms
pulses at 1Hz for 1 h/d) and application of pharmacological inhibitor of myosin-actin
contraction/ATPase (1 h/d during STIM), or mechanical stretch (±Stretch; 5% for 1 h/d),
on myotube myosin content, protein synthesis and markers of proteolysis. (A) Application
of N-benzyl-p-toluene sulphonamide (BTS; 50µM) during STIM bouts over 3 d of DOX
administration mitigates the protective effects of STIM on myotube myosin content
(n=6/bar; P<0.01 DOX effect). (B) Application of 5% stretch prevents increases in MuRF1
expression (n=6/bar, except DOX, where n=7 for all stretch experiments; P<0.01 DOX by
Stretch interaction) and (C) reductions in phosphorylation of FoxO3a (S253; P<0.05 DOX
by Stretch interaction) associated with 1 d of DOX administration. For panel C, DOX was
lower than all other groups (P<0.05) and DOX+Stretch was higher than all groups at
P<0.05, except DOX, where P<0.01. (D) Representative gel image of protein synthesis
measurements using incorporation of puromycin into protein, as described in Methods
section, for a sub-set of replicates with 1 d DOX administration with or without 5%
mechanical stretch for 1 h. (E) DOX administration reduces protein synthesis (P<0.01
DOX by Stretch interaction). (F) For phosphorylation of p70 S6 kinase (p-p70S6k; T308),
DOX (P<0.01) and Stretch (P<0.01) effects were significant, but not DOX by Stretch
interaction effect. Data are mean ± SEM, with individual data points shown with each bar.
*, P<0.05 and **, P<0.01 for DOX (panel A) or DOX by Stretch interaction effects (panels
B, C, E and F), with pairwise differences detailed above, as determined by two-way
ANOVA.
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Figure 4.0.6: Capsaicin effects on myosin content.
182

Figure 6. Effects of capsaicin (CAP) or doxorubicin (DOX; 0.2 µM) administration, with
or without capsaicin administration (CAP), on myotube myosin content. (A) Doseresponse effects of 3 d of CAP administration (50nM, 100nM, 250nM, 500nM, 1µM) vs.
DMSO vehicle CTRL on myotube myosin content (n=3/bar; one-way ANOVA). (B)
Treatment with CAP (100 nM) was unable to prevent the effect of 3 d of DOX
administration to reduce myotube myosin protein content (n=6/bar; P<0.01 DOX effect;
two-way ANOVA). (C) Similar results were found with administration of high
concentration CAP (1 μM) (n=6/bar, except control bars, which are n=3/bar; P<0.01 DOX
effect; two-way ANOVA). Representative gel images are shown at the top of panels A, B
and C for a sub-set of replicates. Note that the representative gel at the top of the panel for
a sub-set of replicates was run on a 7.5% gel, which caused separation of myosin isoforms.
Both bands were quantified. Data are mean ± SEM, with individual data points shown with
each bar. *, P<0.05 and **, P<0.01 compared to vehicle control (panel A) or to denote
DOX effects.
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Figure 4.0.7: STIM induced mitochondrial changes.
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Figure 7. Effects of doxorubicin (DOX; 0.2 µM; gray bars) or vehicle (DMSO; open bars)
administration, with or without electrical field stimulation (±STIM; 20V, 12 ms pulses at
1Hz for 1 h/d) or a 5% static stretch, on mitochondrial reactive oxygen species (ROS)
production, mitochondrial content and anti-oxidant gene expression. (A) 1 and 3 d of DOX
administration increases myotube mitochondrial ROS production per unit mitochondria
measured with MitoSox and MitoTracker fluorescent dyes, respectively (n=12/bar; P<0.01
DOX effect). (B) 3 d of DOX administration, but not 1 d, reduces myotube mitochondrial
content measured by MitoTracker fluorescent dye (n=22/bar; P<0.05 DOX by time
interaction). (C) DOX (P<0.01) and STIM (both STIM and DOX+STIM; P<0.01)
increased mitochondrial ROS production during 3 d of DOX administration relative to
controls (n=6/bar; P<0.01 DOX by STIM interaction). (D) STIM prevented DOX-induced
mitochondrial loss (n=6/bar; P<0.05 DOX by STIM interaction). (E) 3 d of STIM
upregulated PGC-1α alone and with DOX treatment (P<0.05 STIM effect), whereas DOX
increased TFAM (n=6/bar; P<0.01 DOX effect). (F) No DOX by STIM interaction for 1 d
but a STIM effect (P<0.05) was noted on phosphorylation of AMPK (p-AMPK; T172;
n=9/bar). (G) DOX administration (1 d) increases FoxO3a phosphorylation (p-FoxO3a;
S413; P<0.05) and STIM prevents this increase (n=6/bar; P=0.06 DOX by STIM
interaction). (H) DOX administration (1 d) increases FoxO3a phosphorylation (p-FoxO3a;
S413; P<0.06 DOX by STIM interaction; P<0.05 DOX higher than all other groups). (H)
DOX increased FoxO3a phosphorylation (S413; P<0.05) and mechanical stretch was
unable to fully reduce this increase (n=6/bar, except DOX, where n=7; P<0.05 DOX by
Stretch interaction). Data are mean ± SEM, with individual data points shown with each
bar. *, P<0.05; ** and P<0.01 for DOX or DOX by time/STIM/Stretch interaction effects,
with pairwise differences detailed above using two-way ANOVA.
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Figure 4.0.8: Antioxidant enzyme expression.
186

Figure 8. Effects of doxorubicin (DOX; 0.2 µM; gray bars) or vehicle (DMSO; open bars)
administration, with or without electrical field stimulation (STIM; 20V, 12 ms pulses at
1Hz for 1 h/d), on anti-oxidant gene expression. (A) 3 d STIM and DOX both increased
Nrf2 expression (n=6/bar; P<0.05 DOX effect and P<0.01 STIM effect), but had no effect
on KEAP1 (n=3/bar). (B) DOX increased SOD1, SOD2 and CAT expression, independent
of STIM (n=6/bar; P<0.01 DOX effect). (C) DOX upregulated GCLM, independent of
STIM (P<0.01 DOX effect) and DOX alone upregulated GCLC and GPx1 (P<0.05 DOX
by STIM interaction) (n=6/bar). Data are mean ± SEM, with individual data points shown
with each bar. *, P<0.05 and ** P<0.01 for DOX or DOX by STIM interactions, with
pairwise comparisons noted above using two-way ANOVA.
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Table 4.4: Primer sequences for gene expression analysis.
Gene

Forward 5' to 3'

Reverse 5' to 3'

Cat

CGAGGGTCACGAACTGTGTC

GGTCACCCACGATATCACCA

Gclc

ATCTGCAAAGGCGGCAAC

ACTCCTCTGCAGCTGGCTC

Gclm

AGTTGGAGCAGCTGTATCAG

TTTAGCAAAGGCAGTCAAA

Gpx1

CCTCAAGTACGTCCGACCTG

CAATGTCGTTGCGGCACACC

Sod1

ATGGGTTCCACGTCCATCAG

TGCCCAGGTCTCCAACA

Sod2

GAGAATCTCAGTGCTCACTC

GGAACCCTAAATGCTGCCA

Ppargc1a

AAACCACACCCACAG

TCTTCGCTTTATTGCTCGA

(PGC-1α)
Tfam

GATCAG
CACCCAGATGCAAAACTTTC

CTGCTCTTTATACTTGCTCA

Keap1

TGGCCAAGCAAGAGGAGTTC

GGCTGATGAGGGTCACCAG

Nfe2l2

CGAGATATACGCAGGAGAGG GCTCGACAATGTTCTCCAGC

GAPDH

ACGACCCCTTCATTGACCTC

TTCACACCCATCACAAACAT

Cat, catalase; Gclc, glutamate cysteine ligase catalytic subunit; Gclm, glutamate cysteine
ligase modulating subunit; Gpx1, glutathione peroxidase; Sod1/Sod2, superoxide
dismutase 1/2; Ppargc1a, peroxisome proliferator-activated receptor gamma coactivator 1alpha; Tfam, transcription factor A mitochondrial; Keap1, kelch-like ECH-associated
protein; Nfe2l2, nuclear factor erythroid 2 like 2; GAPDH, glyceraldehyde phosphate
dehydrogenase.
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Supplemental figures

Supplemental Figure 4.0.1: Raw tracings of Fluo-2 AMderived intracellular Ca2+ cycling and contractions.
Supplemental Figure 1. (A) Raw tracings of Fluo-2 AM-derived intracellular Ca2+
cycling (top portion of panel) and contractions (bottom portion of panel) of myotube during
20V, 12 ms STIM at 1Hz and its response to tetrodotoxin (TTX; 10µM; red dotted line),
showing cessation of all Ca2+ cycling and contraction. Note that random spikes of
contractile activity of the myotube upon application and following TTX are due to debris
floating through the field where cellular landmarks were chosen to track contractile
activity. These are most prevalent upon initial application of TTX due to fluid shear effects.
(B) Raw tracings of Fluo-2 AM-derived intracellular Ca2+ cycling (top portion of panel)
and contractions (bottom portion of panel) of myotube during 20V, 12 ms STIM at 1Hz
and its response to N-benzyl-p-toluene sulphonamide (BTS; 50µM; 1st red dotted line),
followed by tetrodotoxin (TTX; 10µM; 2nd dotted red line). This tracing shows that BTS
causes cessation of contraction without altering Ca2+ cycling, with the latter being
abolished by TTX.
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Supplemental Figure 4.0.2: Effects of 1d
doxorubicin treatment on p-Akt.
Supplemental Figure 2. Effects of 1 d of doxorubicin (DOX; 0.2 µM; gray bars) or vehicle
(DMSO; open bars) administration, with or without electrical field stimulation (STIM;
20V, 12 ms pulses at 1Hz for 1 h/d) on Akt phosphorylation. STIM reduced
phosphorylation of Akt (p-Akt; T308) after 1 d (P<0.01 STIM effect). Representative gel
images of p-Akt and total Akt expression are shown at the top of the panel for a sub-set of
replicates. All data are mean ± SEM, with individual data points shown with each bar. *,
P<0.05 for STIM effect by two-way ANOVA.
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Supplemental Figure 4.0.3: Effects of DOX and CAP
on mitochondria.
Supplemental Figure 3. Effects of doxorubicin (DOX; 0.2 µM) administration, with or
without capsaicin administration (CAP; 100 nM), on mitochondrial ROS production and
content. A) CAP administration was unable to mitigate the effects of 3 d of DOX
administration to increase ROS production (n=6/bar; P<0.01 DOX effect) or (B) prevent
the loss of mitochondrial content (n=10/bar; P<0.01 DOX effect). All data are mean ±
SEM, with individual data points shown with each bar. *, P<0.05 and **, P<0.01 for DOX
effects by two-way ANOVA.
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Supplemental Figure 4 0.4: Effects of 1hr DOX
treatment on p-AMPK.

Supplemental Figure 4. Effects of 1 hour of doxorubicin (DOX; 0.2 µM; gray bars) or
vehicle (DMSO; open bars) administration, with or without electrical field stimulation
(STIM; 20V, 12 ms pulses at 1Hz for 1 h/d) on AMPK phosphorylation. (A) No effect of
DOX or STIM for 1 h was found on phosphorylation of AMPK (p-AMPK; T172).
Representative gel images of p-AMPK and total AMPK expression are shown at the top of
the panel for a sub-set of replicates. All data are mean ± SEM, with individual data points
shown with each bar.
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Supplemental videos

Supplementalal Video 1 10um scale.avi

Supplemental Video 4.0.1: Intracellular Ca2+ cycling in d7 myotube.
Supplemental Video 1. Pseudocolor video of intracellular Ca2+ cycling in d7 myotube
measured by Fluo-2 AM in response to 20V, 12 ms pulses at 1Hz. Time signatures for each
image are provided at the bottom (frame rate=40/s, scale bar=10 µm).

supplemental video 2 10um scale.avi

Supplemental Video 4.0.2: Contractile dynamics in d7 C2C12 myotubes.
Supplemental Video 2. Contractile dynamics in d7 C2C12 myotubes with 2 μm latex
beads (1:1000) in response to 20V, 12 ms pulses at 1Hz. Time signatures provided at the
bottom (frame rate=10/s, scale bar=10 µm).
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CHAPTER 5: COMPREHENSIVE DISCUSSION

Introduction
There is a consensus that cancer-related muscle wasting might be caused by
multiple tumor factors, host-derived factors, and cancer treatments (5). Muscle wasting is
a primary marker for serious clinical consequences such as physical impairment,
increased morbidity, and increased mortality. Although studies into the cause of cancerrelated muscle atrophy have spanned multiple decades, clinical trials addressing them
individually have proven ineffective (1, 8, 9), and little is known about the mechanisms
and effects of various cancers and their treatments on skeletal muscle. The overall aim of
this dissertation was to identify and understand the mediators of muscle wasting in cancer
patients and to examine the role of muscle contraction to help maintain muscle size and
function. To address these questions we studied two different populations of cancer
patients (lung and breast cancer) to tease out the effects of tumor-derived factors or
chemotherapeutics to cause atrophy and used an in vitro skeletal muscle system to
elucidate the mechanism by which muscle contraction may be beneficial.
Regulation of skeletal muscle mass
In the first part of this dissertation, our goal was to identify and understand the
mediators of muscle wasting in cancer patients. We utilized an in vitro skeletal muscle
system to examine the effects of tumor factors from patients and chemotherapies used in
treatment to directly affect skeletal muscle mass. Our methodology involved treating
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myotubes differentiated to the point that they showed stable myosin contact/myotube
size, expressed myofilament proteins and arranged these into functioning sarcomeres. Of
note, studies in the cancer cachexia field that have examined tumor-related factors using
myotube cultures often compare conditioned media treated cells with non-treated
controls. We found these studies insufficiently controlled and added dilution and noncancer cell controls.
When we examined murine and patient tumor conditioned media (CM) to promote
atrophy and affect mitochondrial health on fully mature myotubes, we found no effect of
the CM. Collectively, our results argue against the hypothesis that there is a direct effect of
tumor derived factors to cause atrophy and/or perturb mitochondrial health. We could
recapitulate findings from other labs that tumor-conditioned media caused reduced
myotube myosin content, but our dilution and non-cancer cell controls suggest that these
results are most likely related to CM inhibiting myotube growth.
In breast cancer patients undergoing chemotherapy treatment, we observed reduced
single muscle fiber CSA, mitochondrial content and increased oxidative stress. Cancer
patients are often treated with chemotherapy, whose side effects are at times
underestimated. Applying our in vitro model to test the effects of chemotherapy to directly
affect skeletal muscle cells, we found similar phenotypes of muscle atrophy, mitochondrial
rarefaction and increased ROS production. Moreover, diminishing mitochondrial ROS
stress with a mitochondrial-targeted anti-oxidant was sufficient to prevent myotube
atrophy.
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There are limitations of our cell culture findings in both of the aforementioned
studies. Thus, we have outlined several future experiments to address these limitations.
For conditioned media experiments, the bolus treatment protocol that we used does
not simulate conditions found in vivo, where muscle is exposed to ongoing kinetics of
constant tumor secretion of factors that could influence muscle. This could be remedied by
the application of a “trasnwell” co-culture model, where human tumor cells are placed in
the same chamber as mature myotubes allowing the media to be shared between both cell
types. The primary outcomes for this experiment would be myosin content, mitochondrial
ROS and mitochondrial content. However, this constant and high concentration of CM may
provide an exaggeratedly high level of tumor-related factors for muscle, similar to animal
models, where tumors exceed 5% of their mass before cachexia is seen. Thus, while this
type of transwell approach may better reproduce the kinetics of tumor secreted factors, it
still suffers the problem of supraphysiological doses of those factors.
Perhaps more importantly, CM from a monolayer of cultured tumor cells may not
adequately reflect tumor production of secreted factors to cause the phenotype seen in
xenograft models (2-4). That is, tumors exist in a three-dimensional environment in vivo
and there is evidence that monolayers of cells do not reflect the behavior of solid, 3D
tumors. Cancer organoids are cancer cells grown in a 3D system with near-physiological
architectures that are reported to retain specific functions of the parent tumors. Using this
technique of growing tumor cells in vitro, lung cancer patients biopsied cells can be grown
into organoids and the CM collected for the bolus experimental model on mature C2C12
myotubes. This organoid system can also be applied to recapitulate drug responses of
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tumors when treated with cisplatin (CIS), paclitaxel (TAXOL) or doxorubicin (DOX), the
CM can be collected for treatment of mature C2C12 myotubes. The primary outcomes for
these sets of experiments would be myotube myosin content and mitochondrial health. Use
of organoid cultures of human tumors would provide the most clinically relevant system for
preclinical evaluation of the effects of tumor-related factors on myotubes (12, 14).
As previously mentioned, non-muscle host factors may contribute to muscle
wasting in cancer patients, as skeletal muscle atrophy in pre-clinical models are often
associated with heightened inflammatory mediators and upregulation of inflammatory
signaling in skeletal muscle. This is also characterized by recruitment of immune cells to
skeletal muscle. The origins of cytokines are still debated, but an alternative hypothesis in
the field is that tumor-derived factors may contribute to muscle wasting by inciting host
immune responses (6). Indeed, the presence of the tumor itself causes the body to produce
an acute phase response (11), and macrophages appear to be the source of some of the
principal mediators of cachexia, such as TNF-α or IL6 (7). Conducting in vitro co-culture
experiments such as described by Venter et al (13), to investigate the effects of
stimulating macrophages with tumor conditioned media on cultured muscle could be used
to increase our understanding of these cellular interactions The communication between
nonmyogenic cells, such as macrophages and fibroblasts are crucial for skeletal muscle
(13). Designing a co-culture experiment in which macrophages are in close proximity to
mature C2C12 myotubes and treated with either standard patient CM (monolayer) or
organoid CM may yield results that better emulate the phenotype described in patients,
with primary outcomes of myosin content and mitochondrial health. This same
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experiment could also be conducted with tumor cells that have been activated with
chemotherapy, where the activated CM is used to treat the co-culture system.
A primary outcome for many of these proposed experiments have been
mitochondrial health. Mitochondria sustain the energy required for normal muscle
homeostasis. However, the role of mitochondria extends beyond energy homeostasis in
muscle. With our model, we were able to inhibit the negative effects of DOX and TAXOL
to cause atrophy, mitochondrial ROS and mitochondrial loss, by treating the mature
myotubes with the antioxidant compound MitoQ. The coupling mechanisms between
redox homeostasis, mitochondrial morphology and muscle size are still unclear.
Mitochondria are able to change their morphology by undergoing either fusion to form
elongated interconnected networks, or fission to generate fragmented disconnected
mitochondria. Healthy mitochondrial dynamics are required for mitochondrial biogenesis
via PGC-1a, for the quality-control of the organelles, and may play a role in apoptosis,
redox homeostasis and mitochondrial dynamics. Designing experiments that identify and
test these important mediators will be important to further elucidate how chemotherapyinduced modifications in mitochondrial content and function contribute to muscle atrophy
during cancer treatment. Such experiments would include treating mature myotubes with
DOX or other oxidants looking for the activation, expression and content of
mitochondrial morphology regulators such as Optic Atrophy 1 (Opa1, fusion) which is
inhibited by S-nitrosylation and increased by denitrosylation, and Dynamin-1-related
protein (Drp1, Fission) whose activity is regulated by ROS via S-nitrosylation, leading to
increased fission. Increased mitochondrial fission has been linked with skeletal muscle
atrophy and experiments that test for this connection may provide more insight into the
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interplay between ROS, mitochondrial fission/loss and skeletal muscle health. One such
experiment would be to utilize a pharmacological inhibitor of Dpr1 such as mdivi-1 in
cultured muscle when treated with DOX to prevent atrophy by reducing mitochondrial
fission. The primary outcomes of these experiments would be myosin content and Drp1
content/phosphorylation/RNA, along with mitochondrial ROS measurements. A genetic
approach can also be used. Using the C2C12 cell line, it is possible to generate a Drp1
knockdown (KD) model in mature myotubes. This KD model can then be tested with
chemotherapies such as DOX, and evaluated for protection of mitochondrial health and
further validated in an in vivo knockout model along with western blots for patients Drp1
for confirmation of phenotype clinically. Similar experiments can be performed with the
overexpression of PGC-1α, if mitochondrial biogenesis is important, it should prevent the
deleterious effects of DOX and other chemotherapies
Exercise
We established an experimental protocol to simulate some of the exercise-induced
changes in gene and protein expression in cultured muscle cell using myotube contraction
via electrical stimulation (STIM). However, three bouts of STIM on cultured cells may
not completely reflect the complexity and time-dependent adaptation of skeletal muscle
to exercise as in vivo. The determination of protein levels, enzymatic activity and
functional read-outs might differ between the cells in culture and muscle in vivo. Testing
these effects in an in vivo model may further support the results from the cell culture
experiments. Using standard wildtype mice experiments with DOX can be performed
with STIM on one leg, with the contralateral leg serving as a control. The outcomes for
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these experiments would be muscle size measured by CSA, mitochondrial ROS measured
by Amplex red assay, and mitochondrial content measured with electron microscopy.
Secondary outcomes would include western blots for mitochondrial dynamics (Drp1,
OPA1), antioxidant enzymes and PGC-1α content. We can further apply this in patients
by utilizing neuromuscular electoral stimulation (NMES) with protocols informed by cell
and animal studies, using the same metrics for primary and secondary outcomes.
In any case, the cell culture experimental system allows the delineation of molecular
mechanisms important for the contracting muscle fiber that cannot be performed on
muscle in vivo. In the future, this model system will have to be adapted and refined such
as with co-cultures, but also importantly, with validation of the mechanical stress
stimulus we previously reported. This would be achieved by applying a cyclical
mechanical stretch with or without DOX matching the in vitro STIM protocol of 1Hz for
1 hour, but limiting the strain to 3.5% as reported by our studies. With this stretch system
we can further delve into the mechanisms of the mechanical forces involved in
maintaining muscle mass.
Calcium signaling has been reported as an important mediator of muscle health. Our
studies with STIM has diminished their importance in this model of mechanotransduction
with the negative results of the transient receptor potential cation channel subfamily V
member 1 (TrpV1) agonist capsaicin and the BTS experiments. However, stretch
activated calcium channels have also been implicated as an important signaling aspect of
mechanical stretch. Using pharmacological inhibitors, such as GsMTX4, of these stretch
activated calcium channels, might help rule out their importance, by showing no
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inhibition in the effects of STIM or stretch to prevent atrophy. Further, applying BTS
during stretch may solidify the importance of mechanical activation of mechano sensitive
proteins by blocking the anti-atrophic effects of stretch.
Calcium release occurs during excitation-contraction coupling (ECC) and our data
shows that STIM works via this system to induce contracture in cultured muscle cells.
However, specifically targeting the main channel of calcium release in the cells has not
been fully characterized. Ryanodine receptors (RyRs) are an important component of
ECC that can be targeted. There are evidence that RyR agonist can be utilized to induce
calcium and have been linked with anti-atrophic effects. We suspect this is due to
coupled contractures, and utilizing RyR agonist Caffeine at 4mM and 4-Chloro-m-cresol
(4CmC) we can elucidate these mechanisms. With the IonOptix system that we have
previously demonstrated, experiments can be performed to test the calcium and
contracture dynamics of these agonists on C2C12 mature myotubes with and without
DOX. We can also apply inhibitors of ECC such as the myosin ATPase inhibitor BTS
and the sodium channel blocker TTX as previously described, to validate the effects to
caffeine and 4CMC to target the RyR and the importance of contracture in their
beneficial effects. The primary outcomes for these experiments would be myotube
myosin content and mitochondrial health with the secondary outcomes of mitochondrial
fusion and fission dynamics.
A common phenotype of cancer patients is muscle weakness and fatigue. Muscle
atrophy and intrinsic weakness likely contribute to these symptoms, but the nature of
these muscle functional deficits remain unknown. Our lab has collected data showing that
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single muscle fibers from cancer patients are not inherently weaker than matched
controls. Thus, impaired myofilament contractility does not appear to be the cause of
weakness. An alternative mediator is impairments in ECC, in particular secondary to
chemotherapy-induced ROS production. We can delve deeper into the effects of
chemotherapy to perturb calcium responses and contracture dynamics. Overnight
treatment with chemotherapies like DOX (0.2µM to 1µM) on mature myotubes might
yield a reduction in response to STIM or a reduction in the fractional strain of the
contracture. Moreover, we can then examine the importance of mitochondrial health or
ROS to affect these calcium and contracture dynamics. Using the previously described
MitoQ at 0.25µM, to inhibit mitochondrial ROS, during DOX treatment may prevent any
deleterious effects of DOX to alter myotube ECC and/or contracture dynamics. Using the
C2C12 cell line, it is possible to generate a PGC-1a knockdown (KD) model in mature
myotubes. This KD model can then be tested with chemotherapies such as DOX, during
electrical stimulation, and evaluated for any loss of anti-atrophic effects of exercise via
loss of mitochondrial health and further validated in an in vivo knockout model along
with western blots for patients Drp1and Pgc-1a for confirmation of phenotype clinically.
The studies discussed have been designed around the murine C2C12 skeletal muscle
cell line. This is a transformed cell line that may not fully match in vivo muscle, therefore
conducting all these studies on primary human muscle cells may provide a clearer picture
of the changes in patient muscle. There are commercially available Human Skeletal
Muscle Myoblasts, which can be used as a consistent control cell line to conduct all
experiments mentioned. However, the most relevant option is to use primary human
myoblasts from muscle biopsies which are a valuable resource for modeling human
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muscle disease in vitro. Human skeletal muscle biopsies often contain extensive
populations of non-myogenic cells, such as adipocytes and fibroblasts, adding to the
complexity of isolating primary cells from patients. Thus, developing proper isolation
techniques such as those published by Spinazzola et al (10) will be important before they
can be utilized for modelling studies. Besides exercise, molecules acting as exercise
mimetics might also be of interest in the attempt to counteract the adverse side effects of
chemotherapeutical agents. This would most likely occur when such adverse effects are
mostly reversible and mainly involve preventing mitochondrial impairment.
Conclusion
Performing clinical trials in cancer patients with muscle wasting is very
challenging and high drop‐out rates are common. Well‐designed preclinical models still
have a vital role to play in screening different potential myoprotective treatments and
guiding the selection of the best candidates for more detailed clinical testing.
Experiments using cultured myotubes are a key step in investigating the direct effects of
catabolic agents and to determine the protective effect of anti‐muscle atrophy treatments.
Typically, experimental outcomes employ measurements of myotube morphology (e.g.,
fiber diameter) and we have expanded this to include myosin content and the expression
levels of anabolic and catabolic mediators in muscle. Several approaches to improve the
modeling of muscle in an in vitro setting have been described. These have included the
use of two or three‐dimensional systems, co-culturing techniques, and use of electrical
stimulation. Ideally, attempts would be made to test myotube responses that combine
several features of the in vivo milieu to study disease‐related muscle atrophy.
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Cancer-related skeletal muscle wasting is a complex syndrome with multiple
contributing factors and signaling pathways. Increasing our knowledge of the
mechanisms involved in muscle wasting, and how mechanical stimulation prevents this
will help point the way to developing treatments. This work makes important
contributions to the field by informing the direction and design of future clinical
interventions in the management of cancer-related muscle atrophy. In conclusion, our
findings have uncovered previously unknown relationships that will inform clinical best
practice and improve patient outcome.
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